Previous Article | Next Article 
Molecular and Cellular Biology, October 2000, p. 7463-7479, Vol. 20, No. 20
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Cooperative Assembly of an hnRNP Complex Induced by
a Tissue-Specific Homolog of Polypyrimidine Tract Binding
Protein
Vadim
Markovtsov,1
Julia M.
Nikolic,2
Joseph A.
Goldman,1
Christoph W.
Turck,3
Min-Yuan
Chou,2 and
Douglas L.
Black1,2,*
Department of Microbiology and Molecular
Genetics1 and Howard Hughes Medical
Institute,2 University of California, Los
Angeles, Los Angeles, California 90095, and Howard Hughes
Medical Institute, Department of Medicine and Cardiovascular
Research Institute, University of California, San Francisco, California
941433
Received 13 June 2000/Returned for modification 16 July
2000/Accepted 20 July 2000
 |
ABSTRACT |
Splicing of the c-src N1 exon in neuronal cells depends
in part on an intronic cluster of RNA regulatory elements called the downstream control sequence (DCS). Using site-specific cross-linking, RNA gel shift, and DCS RNA affinity chromatography assays, we characterized the binding of several proteins to specific sites along
the DCS RNA. Heterogeneous nuclear ribonucleoprotein (hnRNP) H,
polypyrimidine tract binding protein (PTB), and KH-type
splicing-regulatory protein (KSRP) each bind to distinct elements
within this sequence. We also identified a new 60-kDa tissue-specific
protein that binds to the CUCUCU splicing repressor element
of the DCS RNA. This protein was purified, partially sequenced, and
cloned. The new protein (neurally enriched homolog of PTB [nPTB]) is
highly homologous to PTB. Unlike PTB, nPTB is enriched in the brain and
in some neural cell lines. Although similar in sequence, nPTB and PTB show significant differences in their properties. nPTB binds more stably to the DCS RNA than PTB does but is a weaker repressor of
splicing in vitro. nPTB also greatly enhances the binding of two other
proteins, hnRNP H and KSRP, to the DCS RNA. These experiments identify
specific cooperative interactions between the proteins that assemble
onto an intricate splicing-regulatory sequence and show how this hnRNP
assembly is altered in different cell types by incorporating different
but highly related proteins.
 |
INTRODUCTION |
Alternative splicing is a common
mechanism for regulating gene expression in eukaryotes, allowing the
generation of diverse proteins from the same primary RNA transcript
(46, 77, 78). The alteration of splice site choice is
thought to be determined by regulatory proteins that bind to the
pre-mRNA transcript and affect spliceosome assembly on particular exons
or splice sites. The best characterized of these splicing-regulatory
proteins are a set of polypeptides called SR proteins that, among many
other properties, bind to exonic splicing enhancer sequences (7, 10, 35, 47, 75). The SR proteins bound to an exonic enhancer are
thought to stimulate spliceosome assembly at the adjacent splice sites.
Another group of pre-mRNA binding proteins are the heterogeneous
nuclear ribonucleoproteins (hnRNPs) (19, 66). These are a
diverse group of molecules that coat nascent pre-mRNAs, forming complex
but little understood hnRNP structures (42, 52). The
assembly of the spliceosome occurs after formation of these hnRNP
complexes, and some hnRNPs have been implicated in splicing regulation.
For example, hnRNP A1 is able to counteract the effect of SR proteins
in some assays and can also apparently repress splicing through
splicing silencer sequences (3, 7, 8, 11, 31). However, the
assembly of a pre-mRNP complex is poorly understood. It is apparently
highly cooperative, but the interactions between the different hnRNPs
in these complexes are mostly unknown.
Although widely expressed, the SR proteins and hnRNPs do vary in
concentration between different tissues (31, 39).
Changes in splicing patterns are thought to be determined, in part, by subtle changes in the combinations of these proteins present in different cell types. Indeed, the ratio of hnRNP A1 to particular SR
proteins can strongly affect the splicing pattern of some transcripts (50, 51). However, it is likely that more tissue-specific proteins also direct changes in splicing; how a cell achieves the
precise tissue-specific control of a splicing pattern is still a mystery.
Polypyrimidine tract binding protein (PTB or hnRNP I) is a member of
the hnRNP group of proteins (24, 26, 61, 74). PTB is
implicated as a negative regulator of splicing for several alternative
exons. In the
-tropomyosin (
TM) pre-mRNA, the skeletal muscle-specific exon 7 is apparently repressed by PTB in nonmuscle tissues (29, 57). This protein also represses the splicing of
-tropomyosin (
TM) exon 3 in smooth muscle (27, 62).
Neuron-specific exons in the c-src,
-aminobutyric acid A
(GABAA)
2 receptor, clathrin light chain B, and
N-methyl-D-aspartate (NMDA) pre-mRNAs are also
thought to be repressed by PTB (2, 13, 81). With the
exception of
TM, these systems are similar in that PTB seems to
repress a highly tissue-specific exon outside of that particular tissue. Although PTB is an apparent inhibitor of splicing, its mechanism of action is not clear. PTB often binds to pyrimidine-rich elements within or near the 3' splice site of the repressed exon (74). In some cases, this PTB can block binding of the
required splicing factor, U2AF, to the 3' splice site (45,
65). However, sequence elements apart from the 3' splice site are
often required for splicing repression, indicating the need for more
than the simple binding of PTB to the 3' splice site (13,
27). It is also not clear how PTB-mediated splicing repression is
relieved in particular cell types. Interestingly, an altered form of
PTB has been found in extracts of neuronal cell lines and rat brain (2, 13). The electrophoretic mobility of this neural protein differs from that of the three known isoforms of HeLa cell PTB, indicating the existence of a tissue-specific form of the polypeptide. It has been speculated that this neural protein may prevent
PTB-mediated repression of particular neuron-specific exons
(28).
We are characterizing the N1 exon of the mouse c-src
pre-mRNA as a model for understanding the neuron-specific regulation of
splicing. The small (18-nucleotide [nt]) exon N1 is inserted into the
src mRNA in neurons but skipped in other cells
(71). This regulation can be observed in vitro using
extracts of nonneural HeLa cells that skip the N1 exon and extracts of
WERI-1 retinoblastoma cells where the N1 exon is spliced. The
regulation of N1 splicing requires two regulatory regions in the
src pre-mRNA (5, 12, 55, 56). The 3' splice site
upstream of the N1 exon is needed for the repression of N1 splicing in
nonneural cells. We have shown that PTB binds to CUCUCU
elements within this 3' splice site and is required for splicing
repression (13, 17). The second N1 regulatory region,
encompassing nt 17 to 142 downstream of the N1 5' splice site, is an
intronic splicing enhancer and is also required for splicing
repression by the upstream elements. Within this enhancer, nt 37 to 70 are highly conserved between mouse and human. This core sequence,
called the downstream control sequence (DCS), contains the
elements GGGGGCUG and UGCAUG that are needed for
the proper function of the N1 enhancer in vivo and have been found in
other intronic splicing enhancers. When present in more than one copy,
the DCS alone can induce high levels of N1 exon splicing in vivo
(56). However, the DCS normally requires adjacent elements
to function properly (55). The DCS binds specific RNA
binding proteins that can be detected in WERI-1 nuclear extract and are
thought to be important for splicing regulation. Three of these
proteins have been identified as hnRNP F, hnRNP H, and the
KH-type splicing-regulatory protein (KSRP) (16, 53, 54).
There are additional unidentified components of the DCS complexes.
Moreover, none of the identified DCS binding proteins is specific to
the WERI extract even though the larger of the observed DCS-RNP
complexes is enriched in this extract over the HeLa extract.
The roles of the individual sequence elements within the DCS and the
proteins that bind to them have been difficult to resolve. In vivo, the
DCS sequence acts as a general splicing enhancer activating splicing to
some extent in either cell type (56). Competition with a DCS
RNA in an in vitro splicing reaction inhibits splicing, implying a
positive role for some DCS RNA binding proteins (5, 53).
Immunodepletion experiments and the direct addition of antibodies to
splicing extract also support this role (16, 53, 54).
However, CUCUCU elements within and around the DCS are also
required for the repression of splicing in nonneural extract (13,
17). The DCS CUCUCU element binds to PTB in HeLa extract. Therefore, some DCS binding proteins are apparently also effectors of splicing repression or derepression.
The structure and assembly of the DCS-RNP complex is poorly understood.
Here we characterize where on the DCS sequence the various DCS binding
proteins contact the RNA and identify some of their protein-protein
interactions. We also report the cloning and characterization of nPTB,
a new protein binding to the CUCUCU element of the DCS RNA
in WERI-1 nuclear extract. nPTB is very similar in sequence to PTB but
is expressed primarily in the brain. The binding properties of nPTB and
its reduced inhibitory activity on splicing imply roles in controlling
the assembly of other splicing-regulatory proteins.
 |
MATERIALS AND METHODS |
DNA constructs and in vitro transcription.
The N70W, BS7,
BS27, H
6, and adenovirus pSPAd constructs are described elsewhere
(13, 41, 53, 68). BS7 and BS27 templates were linearized
with NotI, pSPAd was linearized with SmaI, and
H
6 was linearized with BamHI. The N70A1 template was obtained by placing DCS DNA under control of the T7A1 Escherichia coli RNA polymerase (RNAP) promoter using two-step PCR.
T7 RNA polymerase was used for transcription of N70W, BS7, and BS27.
SP6 RNA polymerase was used for transcription of pSPAd and H
6.
Transcription reactions were carried out in the presence of cap analog
and [
-32P]UTP by standard procedures (13).
Synthesis of 4-thiouridine-substituted RNA.
Site-specific
introduction of 4-S-UTP (a gift of A. Mustaev, Public Health Research
Institute, New York, N.Y.) into the DCS RNA was achieved through the
"walking" transcription method using a His6-tagged
E. coli RNAP bound to Ni-nitrilotriacetic acid agarose (Qiagen) (48, 58). The RNAP used in these experiments was purified, as described elsewhere, from the E. coli strain
bearing the His-tagged
' subunit of polymerase incorporated into the chromosome (a kind gift from R. Landick, University of Wisconsin, Madison, Wis.) RNAP (2 µg) and N70A1 template (2 µg) were
preincubated for 5 min at 37°C in 20 µl of the transcription buffer
TB (50 mM HEPES-HCl [pH 7.9], 100 mM KCl, 10 mM MgCl2),
mixed with 10 µl of Ni-nitrilotriacetic acid beads preequilibrated
with TB, and incubated for another 5 min. To this resin-bound complex, 2 µl of transcription starting mix (200 µM CpUpApC primer and 250 µM each ATP and GTP) was added. After a 5-min incubation, the beads
were washed three times with 1.5 ml of TB. The elongation complex
containing an RNA 11-mer was then walked to a desired position along
the template by repeated alterations of washing and RNA chain extension
with a subset of 10 µM deoxynucleoside triphosphates (NTPs) for 3 min
at room temperature. The radiolabeled NTP and 4-S-UTP were then
introduced into the system, and the reaction mix was incubated for 10 min at room temperature. After three washes with TB, all four NTPs at
final concentrations of 200 µM each were added to generate a runoff
RNA product. The modified RNA thus synthesized was purified on a 12%
denaturing polyacrylamide gel.
Gel mobility shift and UV cross-linking.
UV cross-linking
and gel shift experiments were carried out under the same conditions
reported previously (53). A 4-µl volume (60 µg) of the
WERI-1 or HeLa nuclear extract or the equivalent amount of 40%
ammonium sulfate precipitate fraction (ASP40) was used in the
site-specific cross-linking experiments. After incubation under
splicing conditions in the presence of 13 µg of heparin per ml, the
samples were irradiated with 360-nm UV light on ice for 15 min using a
handheld UV lamp (UVP) and then treated with 1 µg of RNase A each for
15 min at 37°C. The cross-linked proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
visualized on a PhosphorImager (Molecular Dynamics).
In the gel shift experiments, the amount of purified nPTB, PTB, and
recombinant hnRNP H varied from 50 to 800 ng. These proteins
were
incubated with 100,000 cpm (15 fmol) of labeled DCS RNA for
10 min
before being loaded onto a 6% native polyacrylamide gel
(40:1
acrylamide-to-bisacrylamide ratio). The gel was run in 0.5×
Tris-borate-EDTA (TBE) buffer and visualized as described
previously.
Immunoprecipitation and Western blot analysis.
Immunoprecipitation experiments used rabbit polyclonal antibodies
raised against the PTB C-terminal peptide (CGAHHLRVSFSKSTI), the C2742 antiserum against residues 172 to 711 of KSRP, the 4606 antiserum against FUSE binding protein (FBP) (a gift of D. Levens), and
the anti-Sm monoclonal antibody Y12 (a gift of J. Steitz). In a typical
experiment, 10 µl of protein A or GammaBind Plus Sepharose
(Pharmacia), preequilibrated with TETN150 buffer (25 mM Tris [pH
7.5], 5 mM EDTA 150 mM NaCl, 0.1% Triton X-100) and blocked with 2.5 mg of bovine serum albumin per ml in TETN150, was preincubated with 1 to 15 µl of antibody for 1 h at 4°C, washed with TETN150, and
then incubated with the cross-linked sample for 1 h at 4°C.
Western blot analysis also used the following: rabbit antibodies raised
against the C-terminal peptides of KSRP (DB-KS) and U1-70k; full-length
U2AF65 and hnRNP H proteins; mouse monoclonal antibodies
9H10 against hnRNP A1 (G. Dreyfuss), AK-96 against ASF/SF2 (A. Krainer), BB7 against PTB, and MAb104 recognizing phosphorylated SR
proteins (M. Roth and K. Neugebauer); and human sera Hu134 against
nucleolin (P. Bouvet) and LE against LA antigen (J. Steitz).
In vitro splicing.
Each splicing reaction, conducted as
described previously (13), was performed in a mixture
containing 8 µl of WERI-1 extract (approximately 100 µg of
protein). This was supplemented with 40 to 400 ng of nPTB or PTB or
with 0.3 to 3 µl of WERI- or HeLa-derived 0.3M KCl fractions from the
DCS RNA affinity column, providing an equivalent amount of either
protein. These reactions were terminated after a 4-h incubation for the
BS7 and BS27 templates, a 90-min incubation for the adenovirus major
late transcript (SPAd), and a 2-h incubation for the
-globin
transcript (H
· 6).
nPTB purification.
nPTB was purified from 10 ml (150 mg of
protein) of WERI-1 nuclear extract by using a method modified from that
described previously (61). Chromatography over 20-ml
DEAE-Sepharose Fast Flow, 10-ml heparin-Sepharose CL-6B, and 2-ml
poly(U)-Sepharose 4B columns (Pharmacia) resulted in a fraction
containing a mixture of PTB and nPTB proteins. A 1-ml HiTrap Blue
Sepharose column (Pharmacia) was used next to purify nPTB from
PTB. The poly(U) fraction containing these proteins was loaded on
the column in buffer A (20 mM Tris [pH 8.0], 3 mM
MgCl2, 0.1 mM EDTA, 10% glycerol, 1 mM mercaptoethanol,
0.5 mM phenylmethylsulfonyl fluoride [PMSF]) containing 150 mM
KCl. A 30-ml KCl gradient (150 to 500 mM) was then applied to the
column, resulting in the elution of homogeneous nPTB at approximately
250 mM KCl. The bulk of the PTB eluted at 500 mM KCl. The fractions
containing each protein were combined, dialyzed against buffer DG (20 mM HEPES [pH 7.9], 80 mM potassium glutamate, 1 mM dithiothreitol,
20% glycerol, 0.2 mM EDTA, 0.2 mM PMSF) overnight, and concentrated
using Centricon-30 (Amicon) concentrators. HeLa PTB was purified in a
similar fashion.
RNA affinity column purification.
RNA coupling to adipic
acid hydrazide agarose (Pharmacia) was performed as specified by the
manufacturer. A 40-nmol (470 µg) portion of a chemically synthesized
37-mer DCS RNA
oligonucleotide (CUGAGGCUGGGGGCUGCUCUCUGCAUGUGCUUCCUGG) or the same
amount of a 37-mer UR (unrelated) RNA oligonucleotide
(CGAAUUGGGUACCGGGCCCAGCGCCGCCGUCGUGCCG) was dissolved in 980 µl of 20 mM Tris-HCl (pH 7.5). A 20-µl volume of freshly made 1 M
sodium periodate solution was added, and the mixture was incubated on
ice in the dark for 1 h. Oxidized RNA was ethanol precipitated and
resuspended in 1 ml of 0.1 M sodium acetate (pH 5). This RNA was then
incubated for 3 h at 4°C with 0.5 ml of adipic acid hydrazide
agarose beads preequilibrated with the same buffer. The beads were then
washed with 2 M NaCl and equilibrated with buffer DG. An 8-ml volume of
either HeLa or WERI-1 nuclear extract supplemented with 0.1 mg of
heparin per ml was added to the beads, which were then incubated for
4 h at 4°C with gentle mixing. The slurry was packed into
disposable 2-ml columns and extensively washed either with buffer DG
plus 20 mM KCl or with buffer D (20 mM HEPES [pH 7.9], 100 mM KCl, 1 mM dithiothreitol, 20% glycerol, 0.2 mM EDTA, 0.2 mM PMSF). The bound
proteins were eluted with 4 to 6 ml of buffer A containing 0.3, 0.5, 1, or 2 M KCl or 6 M urea. The fractions were dialyzed against buffer DG
and concentrated to approximately 200 µl using Centricon-10 (Amicon) concentrators.
Proteins of each fraction were resolved by SDS-PAGE (10%
polyacrylamide) and analyzed by nanospray mass spectrometry (MS).
Coomassie blue-stained proteins from the gel were subjected to
an
in-gel digestion with Endoproteinase Lys-C (Roche Diagnostics),
and the
extracted peptides were desalted over a 100-nl gel loader
pipette tip
column filled with POROS R2 resin (Perseptive Biosystems).
The peptides
were eluted off the resin in 1 µl of 50% methanol-5%
formic acid
into a nanospray glass capillary (PROTANA). The peptide
solution was
then infused into an LCQ mass spectrometer (FinniganMat),
and
individual peptide ions were subjected to tandem MS-MS analysis.
The
acquired MS-MS data were compared to the nonredundant protein
database
(National Center for Biotechnology Information) using
the SEQUEST
software (John Yates and Jimmy Eng, University of
Washington).
Identified proteins were confirmed by Western blot
analysis.
Northern blot analysis.
nPTB cDNA tissue distribution was
assessed using a commercial multiple-human-tissue Northern blot as
specified by the manufacturer (Clontech). The membrane was probed with
a 56-nt nPTB oligonucleotide or nPTB cDNA, a 1-kb PCR-generated
fragment of PTB cDNA (nt 550 to 1448 of the PTB open reading frame), or
a 2.0-kb human
-actin cDNA probe provided with the blot.
Total RNA from each cell line was isolated using the guanidine
thiocyanate method (
15). A 10-µg portion of total cellular
RNA was loaded per lane, separated on a 1% formaldehyde-agarose
gel,
and transferred to a nylon membrane (Schleicher & Schuell).
This blot
was probed with the same

-actin cDNA or PTB cDNA fragments
as the
multiple-tissue Northern blot or with a full-length nPTB
cDNA. The
results were visualized by PhosphoImager (Molecular
Dynamics)
analysis.
nPTB cDNA cloning.
Purified nPTB was subjected to SDS-PAGE
(10% polyacrylamide), and the nPTB band was excised and subjected to
in-gel tryptic digestion. The eluted peptides were fractionated by
high-pressure liquid chromatography on a Vydac C18 column
and sequenced on an automated protein sequencer (Perkin-Elmer model
492). A search of the GenBank database with the peptides that differed
from PTB identified no expressed sequence tag (EST) matches but
resulted in the retrieval of two short bacterial artificial chromosome tags of human genomic clone CIT-HSP 2282L8 (DDBJ/EMBL/GenBank accession
no. AQ000290 and AQ006967). The short identifier sequence from the end
of this clone is in the nPTB exon encoding most of the
NNQFQALLQYGDPVNAQQAK peptide. The 56-nt NNQ oligonucleotide (ATACTCAAGCTCTGCTCCAGTATGGTGATCCAGTAAATGCTCAACAAGCAAAACTA)
encoding most of this peptide was used to probe a WERI-1 cDNA
Lambda Zap library. Six positive clones were obtained. Random hexamer
cDNA synthesis of WERI-1 total RNA followed by PCR using the NNQ
oligonucleotide and a degenerate oligonucleotide corresponding to the
FFQDHK peptide of nPTB resulted in an 821-bp PCR fragment containing
approximately half of the nPTB open reading frame. This PCR product was
then used to probe the same WERI-1 cDNA library. One positive clone identified by both probes was plaque purified and sequenced.
Nucleotide sequence accession number.
The human nPTB cDNA
sequence has been submitted to GenBank and has been given accession no.
AF176085.
 |
RESULTS |
Proteins that bind to individual sequence elements within the DCS
RNA.
The DCS acts in vivo as part of an intronic splicing enhancer
needed for inclusion of the N1 exon (56). The DCS also
contains a CUCUCU element that mediates repression of N1
splicing in nonneural cells and that cross-links to PTB in a
full-length spliceable src RNA (12, 13, 17). A
short DCS RNA probe was previously shown to assemble into two
RNA-protein complexes, "nonspecific" and "specific"
(53). The nonspecific complex can be competed away by any
RNA and is hence non-sequence specific. It is also present in both HeLa
and WERI extracts. This complex contains a prominent 50- to 55-kDa
protein observable by shortwave UV cross-linking. The specific complex
is enriched by removing the 55-kDa protein by ammonium sulfate
fractionation of the extract. This specific complex contains hnRNP H,
hnRNP F, and KSRP as well as other factors. Although present in HeLa
extract, the specific complex is more prominent in WERI extract
(16, 53, 54). This complex is also sequence specific, since
it is competed efficiently only with a DCS RNA. Although PTB binds to
the CUCUCU element of the DCS in a full length pre-mRNA, we
had not previously seen PTB binding to this element in the complexes
formed on a short DCS RNA probe. To characterize proteins interacting
specifically with the CUCUCU element of the DCS, we
generated DCS RNAs where the U's in this element were replaced with
the photoaffinity label 4-thiouridine (4-thioU). The 5' phosphate of
each cytosine in the CUCUCU element was further replaced
with 32P. This modified DCS RNA was incubated with HeLa or
WERI nuclear extract and irradiated with 366-nm UV light. The extract
was treated with RNase A, and the cross-linked proteins were resolved
by SDS-PAGE.
As with shortwave UV cross-linking, 4-thioU cross-linking to the DCS
RNA in the unfractionated extract gave a prominent band
of 50 to 55 kDa
as well as a band of approximately 100 kDa (Fig.
1A lanes 3 and 4). These proteins are
thought to be the La and
nucleolin proteins nonspecifically bound to
the RNA (see below).
4-ThioU cross-linking also gave a 60-kDa band
(marked nPTB) that
was not previously observed with shortwave UV
cross-linking. This
60-kDa protein was more prominent in WERI extract.
We showed previously
that the RNP complex that is specific for the DCS
sequence is
enriched in the 40% ammonium sulfate pellet fraction
(ASP40) of
the extract (
53). 4-ThioU cross-linking in this
fraction again
gave protein bands similar to those seen by shortwave UV
(
53)
(Fig.
1A lanes 1 and 2). These proteins were identified
by immunoprecipitation
(Fig.
1B). The top band, migrating at 80-kDa,
was identified as
KSRP, and the 70-kDa band was identified as FBP,
which is highly
related to KSRP (Fig.
1B, lanes 3 and 4) (
18,
20). The other
prominent band common to both extracts runs at 55 kDa and was
identified as hnRNP H, as indicated by immunoprecipitation
with
Y12 anti-SM antibodies (lane 2). We previously found that hnRNP
H
is recognized by this antibody (
16). KSRP and hnRNP H were
identified earlier as components of the specific DCS complex.
The
coimmunoprecipitation of KSRP and FBP with hnRNP H is presumably
due to
their presence in the same complex, since anti-SM serum
has not been
observed to react with KSRP and FBP. This coimmunoprecipitation
varies
with the reaction conditions and is not seen when precipitating
with
anti-KSRP or anti-FBP antibodies (lanes 3 and 4).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 1.
Structure and composition of the DCS complex. (A) nPTB
cross-links to the CUCUCU element of the DCS RNA. The DCS
RNA sequence is shown at the top. Modified bases are shown as hollow
letters. Site-specific labeling of proteins binding to the DCS RNA is
shown below the sequence. Cross-linking in the ASP40 fraction of WERI-1
(lane 1) or HeLa (lane 2) extract and in total HeLa (lane 3) or WERI-1
(lane 4) nuclear extracts is shown. Positions and sizes of the
molecular weight standards (in thousands) are indicated on the right.
(B) Immunoprecipitation of the proteins binding to the DCS RNA in the
WERI ASP40 fraction. Antibodies used were anti-SM Y12 (lane 2),
anti-KSRP (lane 3), anti-FBP (lane 4), and anti-PTB (lane 5). (C)
Probing hnRNP H, hnRNP F, KSRP, FBP, and nPTB binding sites on the DCS
RNA by site-specific labeling. Modified (hollow) and radiolabeled
nucleotides are shown below the DCS RNA sequence. Cross-linking was
done in the ASP40 fraction of WERI-1 (lanes W) or HeLa (lanes H)
nuclear extract. (D) DCS RNA mutants used in the cross-linking
experiments. Positions of 4-thioU modifications are indicated as
U8 and U18 above the wild-type (WT) sequence,
and the mutations are indicated below. (E) Effect of mutations in DCS
RNA on the cross-linking of proteins to positions U18 (top)
and U8 (bottom) of the DCS in the ASP40 fraction of WERI-1
extract (lanes W) or HeLa extract (lanes H).
|
|
Interestingly, the 60-kDa protein seen binding in the whole nuclear
extract is also enriched in the ASP40 fraction and is
immunoprecipitable with anti-PTB antibodies (Fig.
1B, lane 5).
We
reported earlier on a WERI-specific form of PTB that bound
to the N1 3'
splice site (
13). This may be the same protein
seen here
binding to the DCS sequence in WERI extract. As explained
below, we
call this protein nPTB (for neurally enriched homolog
of PTB). However,
since WERI extract also contains the normal
HeLa form of PTB, these
bands could be mixtures of the two proteins.
Nevertheless, it is clear
that a PTB-related protein binds the
CUCUCU element of the
DCS.
An equivalent DCS-cross-linked PTB band is present in HeLa extract but
is less pronounced. It is not clear why PTB cross-linking
in HeLa
extract is inefficient. It could be that PTB actually
binds less well
to the DCS than nPTB does. Alternatively, the
precise interaction of
nPTB and PTB with the RNA may differ, leading
to inefficient
cross-linking of PTB despite its binding to the
RNA. Given that the DCS
CUCUCU element is needed for splicing
repression in HeLa
extract, we thought that the latter possibility
was more likely (see
below).
We next extended this cross-linking approach to more precisely localize
the binding sites for each protein along the DCS RNA.
By incorporating
the 4-thioU and
32P at different positions, we could assess
which nucleotides were
in close contact with each protein (Fig.
1C).
When the photoaffinity
label was placed just 5' or just 3' of the G5
element in the DCS,
the predominant cross-linked bands were hnRNP H and
F (lanes 1
and 2 and lanes 5 and 6, respectively). This was also seen
when
the RNA was
32P labeled in the G tract without the
4-thioU and the cross-linking
was by shortwave UV (lanes 3 and 4).
Interestingly, hnRNP F, although
present in both extracts, cross-linked
well to the RNA only in
the WERI extract. When the 4-thioU was moved
downstream to the
CU tract, cross-linking to the F protein was lost but
cross-linking
to hnRNP H, nPTB, KSRP, and FBP was seen (lanes 7 to 12).
This
contact with the H protein was primarily with the 5'-most U in
the
CU tract; when the label was only in the central U, the intensity
of
the H band was decreased (lanes 9 and 10). As before, the PTB
band was
enriched in the WERI extract over the HeLa extract. When
the 4-thioU
was placed in the element UGCAUG, just downstream
of the CU
tract, cross-linking was weaker but was predominantly
to KSRP, FBP, and
an unidentified protein of about 50 kDa. With
the label in this
position, cross-linking to PTB or nPTB and to
hnRNP H and F was lost.
The proteins that bind to this position
are particularly interesting
because this UGCAUG element is crucial
to the activity of
the DCS as an enhancer. Overall, these results
give a clearly ordered
arrangement of the proteins along the DCS
sequence, going from 5' to
3', hnRNP H and F then nPTB, then KSRP
and
FBP.
The importance of each element in the binding of the individual
proteins was assessed by repeating the cross-linking on RNAs
where the
small sequence elements were mutated (Fig.
1D and E).
These experiments
used labels in two positions along the RNA sequence,
just 5' of the G
tract (modification U
8 [Fig.
1D and E, bottom])
or within
the CU tract (modification U
18 [Fig.
1D and E, top]).
Cross-linking at U
8 adjacent to the G tract gave
predominantly
the hnRNP H and F proteins as before, unless the G tract
was mutated,
which caused a loss of hnRNP H and F cross-linking (Fig.
1E, bottom).
This was also seen with the label at U
18 and
confirms the need
for the G tract in hnRNP H and F protein binding
(Fig.
1E, lanes
2 and 3). The effects of the other mutations were most
easily
observed with the label at U
18 (Fig.
1E, top).
Mutation of the
CU tract reduced nPTB cross-linking and increased
cross-linking
to the hnRNP H and F proteins (lanes 4 and 5). It is not
clear
whether the increased signal for hnRNP H and F is due to
increased
binding of these proteins to the mutant RNA, perhaps due to
changes
in secondary structure, or to increased interaction with the
label
at this position because of the loss of PTB binding (see below).
Mutation of the GCA sequence within the UGCAUG element does
not
affect nPTB binding but reduces KSRP and FBP binding (compare
lanes
6 and 7 with lanes 8 and 9). In sum, the cross-linking to
the mutant
RNAs confirms the position of contact for each protein
along the
RNA.
The cross-linking experiments delineated the relative position of each
protein along the RNA. However, these experiments did
not give any
information on the stoichiometry of the proteins
binding to the DCS and
did not distinguish how many complexes
are formed by the various
cross-linked proteins. For example,
when we see both KSRP and nPTB
cross-linking, we do not know whether
these are binding
simultaneously in one complex or independently
in separate
complexes. Previous gel shift and antibody supershift
experiments
indicated that hnRNP H and KSRP are in the same complex
(
16,
53,
54). As a first step in testing whether PTB is
also in this
complex with hnRNP H and KSRP, we performed coimmunoprecipitation
experiments (data not shown). Using an anti-PTB monoclonal antibody,
we
immunoprecipitated PTB from HeLa extract in the presence or
absence of
the DCS RNA. KSRP was strongly coprecipitated with
PTB only in the
presence of the DCS RNA, indicating that these
proteins do indeed
interact with the DCS RNA in the same complex
(data not shown). Since
the majority of the KSRP is present in
the DCS complex under these
conditions, these results place PTB
in a complex with both hnRNP H and
KSRP rather than in a complex
that is independent of the previously
characterized DCS complex.
Moreover, since these experiments were done
with HeLa extract
containing PTB rather than nPTB, they demonstrate
that PTB is
indeed binding to the DCS in spite of its weak
cross-linking.
The common binding of these proteins into a single
complex is
addressed further
below.
Characterization of DCS RNA binding proteins by RNA affinity
chromatography.
To further examine the proteins binding to the DCS
RNA in the absence of cross-linking, we performed RNA affinity
chromatography. After periodate treatment, the DCS RNA was chemically
attached through its 3' end to adipoyl hydrazido-Sepharose. We find
that this resin shows lower nonspecific protein binding than do RNA affinity resins based on the avidin-biotin interaction. To further minimize nonspecific protein binding, nuclear extract was supplemented with 0.1 mg of heparin per ml before being loaded on the column. Based
on gel shift data, this amount of heparin disrupts nonspecific RNA-protein complexes while leaving the specific DCS complex intact.
The RNA resin was incubated with either HeLa or WERI nuclear extract,
packed into a column, and washed extensively in 100
mM salt buffer. DCS
RNA binding proteins were then eluted in a
step gradient of KCl. In a
control experiment, a column carrying
RNA unrelated to the DCS sequence
was used. The protein composition
of each fraction was analyzed after
gel separation by Coomassie
blue staining and Western blot analysis
(Fig.
2). The elution
profiles for the
HeLa and WERI nuclear extracts on the DCS RNA
column were very similar.
The most prominent WERI protein, eluting
between 0.3 and 0.5 M salt,
was nPTB, as confirmed by Western
blot using an anti-PTB serum that
reacts with both proteins. In
HeLa extract, PTB eluted in the same
fractions but ran as a doublet
on the gel. Note that due to differences
in the running of the
two gels, they cannot be perfectly aligned. The
PTB in the HeLa
panel is slightly below that in the WERI panel. The
binding of
the nPTB and PTB proteins was very efficient; these proteins
were
almost completely depleted from the WERI flowthrough fraction
(Fig.
2B).

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 2.
Purification of proteins bound to the DCS RNA or an
unrelated RNA in the WERI-1 or HeLa extracts using RNA affinity
chromatography. (A) Coomassie blue-stained gels displaying fractions
from the DCS RNA affinity column (lanes 1 to 6 and lanes 8 to 13) or an
unrelated RNA affinity column (lanes 15 to 20). Proteins identified by
MS are indicated by arrows. Lanes 7, 14, and 21 contain protein
markers. (B) Western blot analysis of the same fractions. MAb104
monoclonal antibody was used for identification of the SR proteins. The
positions of the SC35 and ASF/SF2 (SRP 35), SRp55, and SRp75 proteins
are indicated by arrows.
|
|
Western blot analysis of the column fractions identified other proteins
binding to the DCS RNA. Known components of the DCS
gel shift complex,
KSRP, FBP, and hnRNP H, all bound the DCS RNA
column and eluted in 0.3 to 0.5 M salt (Fig.
2B). By Coomassie
staining, hnRNP H appeared to
bind to the column less efficiently
than nPTB or KSRP did. The control
RNA binding proteins hnRNP
A1 and U2AF65 both failed to bind to the
column and eluted in
the flowthrough fraction. None of these proteins
bound well to
the nonspecific RNA column, although some KSRP and hnRNP
A1 were
present in the 0.3 M
fraction.
Another protein eluting from the DCS RNA column was identified as SC35.
This 35-kDa protein was reactive with MAb104 anti-SR
and anti-SC35
monoclonal antibodies but not with ASF/SF2 antibodies.
This was the
only SR protein seen binding to the DCS column. However,
it also bound
to the unrelated RNA column. Given the known effects
of SR proteins on
splicing, we are investigating whether SC35
plays a role as a DCS
binding protein, even though its binding
specificity is somewhat in
doubt.
Several other proteins also bound to the DCS RNA column. These were
identified by MS analysis of their tryptic peptides as
nucleolin, La
antigen, hnRNP C, and actin. The nucleolin, SC35,
and La antigen
proteins bound tightly to the DCS RNA, eluting
mostly at 0.5 to 1 M
salt. Both La and nucleolin recognize short
stem-loop RNA structures
containing pyrimidine-rich sequences
on their termini, and the DCS RNA
can potentially fold into such
a structure (
22,
25,
70).
Thus, the binding of these proteins
to the column is probably due to
similarities between the DCS
RNA and natural RNA substrates for these
proteins. La is presumably
the ~50-kDa protein observed in the
nonspecific gel shift complex
with the DCS RNA (
53). hnRNP C
eluted from the column at 0.3
M salt. hnRNP C has affinity for
pyrimidine-rich RNAs, and such
elements are present in the DCS RNA
(
69,
72,
73). Some actin
protein was also observed to stick
very tightly to the column,
eluting only in 6 M urea. This may result
from polymerized actin
filaments, trapped at the top of the column,
eluting from the
column when denatured into
monomers.
Most of the proteins binding to the DCS RNA, including nPTB and
PTB, were not retained on the unrelated RNA column, which
showed a
different spectrum of bands. The exceptions to this were
SC35 and
nucleolin, which bound tightly to both RNA columns. The
nucleolin
elution profile varied from batch to batch of the extract.
Note
that there is a prominent nucleolin breakdown product migrating
just
below KSRP in some of the WERI and HeLa extract
fractions.
The RNA affinity chromatography was repeated with RNAs carrying
mutations in each of the various subelements of the DCS RNA
(data not
shown). This confirmed that PTB and nPTB required the
CU tract for
stable binding, hnRNP H binding needed the G tract
and the UGCAUG
element, and KSRP binding needed the CU tract and
the UGCAUG
element.
Finally, the affinity chromatography results indicate that HeLa PTB
binds to the DCS RNA even though it does not cross-link
efficiently.
Moreover, as seen previously, the eluted HeLa PTB
migrates as a doublet
with slightly different mobility from the
WERI nPTB-PTB
mixture.
Purification and cloning of nPTB.
The different cross-linking
patterns of PTB in the two extracts indicated a difference in the
protein from these two sources. To allow a detailed comparison of the
PTBs in the two extracts, we purified the two proteins using a
modification of the published PTB purification protocol
(61). The HeLa and WERI PTBs copurified over the first three
columns: DEAE, heparin, and poly(U)-Sepharose. When the WERI extract
fractions from the poly(U) column were loaded onto a HiTrap Cibacron
Blue Sepharose column and eluted with a shallow gradient of KCl, the
two forms of PTB were resolved. Under these conditions, nPTB came off
the column earlier than the PTB isoforms seen in HeLa extract (Fig.
3A). As a result, a nearly homogeneous
sample of the nPTB protein, free of PTB, was obtained (Fig. 3B).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Purification of human nPTB. (A) Purification scheme.
Coomassie blue-stained gels of PTB- and nPTB-containing fractions from
the HiTrap Blue column are shown below the scheme. (B) Coomassie blue
staining of an SDS-10% polyacrylamide gel containing purified WERI-1
nPTB and HeLa PTB. (C) nPTB peptide sequences identified by Edman
degradation (left) and corresponding human PTB-1 peptides (right).
Differences between two proteins are shown by hollow letters.
|
|
nPTB was subjected to tryptic digestion followed by microsequencing of
seven peptides. Two of the analyzed peptides matched
the PTB sequence
exactly, whereas the others contained one or
more changes in amino acid
sequence from the corresponding PTB
peptides (Fig.
3C). The unique nPTB
peptides were distributed
along the PTB sequence, indicating that nPTB
is a new protein
rather than a new PTB splice
variant.
Searching GenBank databases for the nPTB peptide sequences
resulted in only one positive match. There were no matches to ESTs.
However, the longest identified peptide, NNQFQALLQYGDPVNAQQAK,
matched the sequence from the end of the human genomic BAC
clone
AQ006967. This clone contained 56 nt of an apparent nPTB exon
encoding most of the peptide. Reverse transcription-PCR (RT-PCR)
of
WERI cell total RNA, using the 56-nt exon oligonucleotide as
a
sense-oriented primer and an 18-nt degenerate antisense primer
corresponding to the FFQDHK peptide, produced a partial nPTB cDNA,
821 nt in length. Both the 56-nt exon sequence and the RT-PCR
product were
used to screen a WERI cell

Zap cDNA library. A clone
containing the
apparent full-length cDNA of nPTB was identified
and sequenced (Fig.
4). This 3,060-nt cDNA contains a
1,593-nt
open reading frame encoding a 531-amino-acid 57,454-Da
protein.
All seven nPTB peptides are present in the amino acid sequence
of the encoded protein (Fig.
4).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 4.
Human nPTB cDNA sequence. The NLS sequences are shaded.
The four RRM domains are boxed. Sequenced peptides are in bold. The
asterisk indicates the stop codon.
|
|
As expected, nPTB is very similar to PTB (~74% identical, depending
on how the gaps are weighted), containing four unusual
RNA recognition
motif (RRM) domains and a putative bipartite nuclear
localization
signal (NLS) near the N terminus. This NLS domain
consists of two short
sequences, GVKRG and KKFK, separated by
a 29-amino-acid gap, and
matches the consensus nucleoplasmin NLS
better than the corresponding
PTB domain does (
63) (Fig.
4).
The four 80-amino-acid RRM
domains of nPTB can be aligned with
each other and are similar to the
PTB RRM domains. A typical RRM
domain contains two consensus elements,
RNP1 and RNP2, that comprise

-strands 3 and 1 of the domain
(
32,
60,
76,
79). Like
PTB, the RNP elements of nPTB diverge
from those in the consensus
RRM (Fig.
5A). Alignment of the
four nPTB RRM domains also shows
common residues within

-helix A,
within

-strand 2 and following

-strand 4. In the known structures
of RRMs complexed with RNA,
the

-sheets both form the hydrophobic
core of the domain and
make extensive contact with the RNA on the
interaction surface
(
1,
32,
60,
79). The conservation of the
nPTB sequence
in these regions may reflect folding constraints or could
result
from similarities in RNA recognition.


View larger version (89K):
[in this window]
[in a new window]
|
FIG. 5.
Comparative analysis of the nPTB amino acid sequence.
(A) Structural organization of the nPTB RRMs. RNP1 and RNP2 consensus
sequences for the typical RRM and for the nPTB RRMs are shown at the
top. The domain secondary structure is schematically shown below the
RRM sequences. Residues identical in at least two RRMs are shaded. (B)
Comparison of human nPTB with related PTB sequences. The human nPTB
sequence is aligned with PTB sequences from human (accession no.
X62006), mouse (accession no. X52101), Xenopus laevis
(accession no. AAF00041), D. melanogaster (accession no.
AAF22979), C. elegans (accession no. CAA85411), and
Arabidopsis thaliana (accession no. AF076924), with a
partial sequence of nPTB from Danio rerio (accession no.
AA566427) and with the sequence of human ROD1 (accession no. NM005156)
using the MegAlign program (DNAStar). Residues identical to those of
nPTB are shown as dots. Brackets indicate the borders of RRM domains.
(C) A phylogenetic tree of human nPTB and mammalian, plant, and
C. elegans PTBs generated by MegAlign based on the protein
alignment. The length of the branch on the x axis indicates
the percent sequence divergence.
|
|
The variation in sequence between human nPTB and PTB far exceeds that
between PTBs from different mammals. Human nPTB is presumably
the
homolog of the mouse brain PTB protein recently isolated by
the Darnell
laboratory, since they are nearly identical (accession
no.
AF095718).
An EST database search with the nPTB sequence
also identified the
partial cDNA sequence of an apparent zebrafish
nPTB (accession no.
AA566427). Phylogenetic comparison of the
known PTB sequences places
nPTB on a distinct branch, roughly
equally related to all the mammalian
PTBs (Fig.
5C). nPTB is also
67% identical to ROD1, another mammalian
PTB homolog identified
as a regulator of differentiation in
Schizosaccharomyces pombe (
80). Searches of the
complete
Caenorhabditis elegans and
Drosophila melanogaster genomes each uncovered a single gene with similarity
to PTB. These proteins were divergent from both mammalian proteins,
but
at several positions they were more similar to PTB than nPTB.
These
results are consistent with the idea that nPTB is relatively
recently
evolved and is perhaps specific to the
vertebrates.
Tissue distribution of nPTB.
The biochemical assays for nPTB
indicated its presence in WERI but not HeLa extract. We next examined
the expression of nPTB and PTB on a multiple-tissue Northern blot (Fig.
6A). The full-length nPTB cDNA and a 1-kb
fragment of the PTB coding region were used as probes. A human
-actin cDNA was used as a control. nPTB mRNA appeared as a single
band approximately 3.4 kb in length, while PTB gave rise to a doublet
of 3.6- and 4.7-kb bands. The upper band may be a cross-hybridizing
mRNA or possibly an immature form of PTB mRNA. PTB mRNA was present in
a wide range of tissues, with the lowest levels observed in the brain.
In contrast, nPTB mRNA was most abundantly expressed in the brain,
although there was detectable expression in other tissues, notably the
heart and skeletal muscle.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 6.
Tissue and cell line distribution of nPTB. (A) Northern
blot analysis of poly(A)+ RNA from the indicated human
tissues using an nPTB oligonucleotide probe (top) or the PTB cDNA probe
(middle) probe. Loading was verified by hybridization to a -actin
control cDNA probe (bottom). (B) Northern blot analysis of total RNA
from the indicated neural (lanes 1 and 2) and nonneural (lanes 3 and 4)
cell lines. Probes included the full-length nPTB cDNA (top), a 1-kb
fragment of PTB (middle), and the -actin control cDNA probe
(bottom). (C) Western blot analysis of proteins from neural (lanes 1 to
3) and nonneural (lanes 4 to 6) cell lines using rabbit polyclonal
anti-PTB antibodies recognizing both the PTB and nPTB proteins (top).
The positions of the PTB isoforms and of nPTB are indicated by arrows.
The same blot was probed with anti-U170K antibody as a protein-loading
control (bottom).
|
|
The level of nPTB mRNA was also examined in tissue culture cell lines
(Fig.
6B). Abundant expression was observed in the WERI-1
neural cell
line, as expected. Only minimal mRNA was observed
in the nonneural cell
lines, HeLa and HEK293. Significantly, only
low levels of nPTB mRNA
were seen in the human neuroblastoma cell
line, LA-N-5. This was
confirmed by RT-PCR experiments, where
LA-N-5 cells showed higher
expression of nPTB mRNA than did HeLa
or HEK cells but significantly
lower expression than did WERI-1
cells (data not shown). Since LA-N-5
cells show strong inclusion
of the
src N1 exon, the level of
nPTB is not the only factor that
determines N1 splicing. These cell
lines all expressed abundant
PTB mRNA, confirming that WERI cells
express both PTB and nPTB
(Fig.
6B). This was further confirmed by
Western blot analysis
(Fig.
6C). nPTB could be observed in WERI cells
as a reactive
band running between the two major isoforms of
PTB.
nPTB is a weaker repressor of N1 splicing than is PTB.
To
assess the functional differences between nPTB and PTB, we analyzed the
behavior of each protein in the in vitro splicing assay by using two
src minigene transcripts. BS7 contains both the upstream and
downstream regulatory sequences, each containing a pair of CUCUCU
elements (Fig. 7A). BS27, obtained
by precise deletion of the intron upstream of the N1 exon, contains
only the two downstream CUCUCU elements. We previously
showed that BS27 is spliced in the HeLa nuclear extract, where BS7 is
repressed. Both transcripts splice equally well in WERI extract
(12).


View larger version (148K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of PTB and nPTB on N1 exon splicing in vitro. (A)
Maps of the src splicing substrates. Black boxes indicate
splicing-regulatory elements. (B) Splicing of adenovirus major late
(lanes 1 to 8) and -globin (lanes 9 to 16) transcripts in WERI-1
nuclear extract in the absence (lanes 2 and 10) or presence of 0.3, 1, or 3 µl of HeLa (lanes 3 to 5 and 14 to 16) or WERI-1 (lanes 6 to 8 and 11 to 13) 0.3 M KCl RNA affinity fractions. (C) The left panel
shows splicing of the BS27 (lanes 1 to 8) or BS7 (lanes 9 to 22)
transcripts in the WERI-1 nuclear extract. Lanes 1 and 9 contain no
extract. Lanes 2 and 10 contain WERI extract without any additional
factors. Lanes 3 to 5 and 14 to 16 contain WERI extract plus 0.3, 1, or
3 µl of HeLa 0.3 M KCl RNA affinity fraction. Lanes 6 to 8 and 11 to
13 contain WERI extract plus 0.3, 1, or 3 µl of WERI 0.3 M KCl RNA
affinity fraction. Lanes 17 to 19 contain 40, 120, or 400 ng of nPTB.
Lanes 20 to 22 contain 40, 120, or 400 ng of PTB. The right panel shows
splicing of BS7 transcript in the WERI-1 nuclear extract using
different preparations of nPTB, PTB, and nuclear extract from the left
panel. Lane 1 contains WERI extract without any additional factors.
Lanes 2 to 5 contain 50, 100, 200, or 400 ng of nPTB. Lanes 6 to 9 contain 50, 100, 200, or 400 ng of PTB.
|
|
Purified HeLa PTB efficiently repressed BS7 splicing when titrated into
the WERI nuclear extract (Fig.
7C, left, lanes 20
to 22). The levels of
both the splicing intermediates and products
were decreased 3- to
10-fold by the added PTB. Similarly, the
0.3 M fraction of the HeLa
extract from the DCS RNA column (Fig.
2) also repressed splicing (Fig.
7C, left, lanes 14 to 16). The
splicing repression required the same
amount of PTB whether it
was introduced as 0.3 M fraction or as a
purified protein. At
the highest point of the titration, the total PTB
concentration
was about twofold higher than that of the endogenous
protein in
HeLa extract. Bacterially expressed recombinant PTB also
repressed
splicing but was about 10 times less active than the purified
protein (data not shown). This may be due to aberrant folding
of the
recombinant protein, to a lack of posttranscriptional modification,
or
to other
effects.
PTB was a much stronger repressor of splicing than was nPTB. At the
highest concentration of nPTB, the levels of the second-step
products
of splicing were somewhat reduced but the levels of the
intermediate
products of the first step were unaffected (Fig.
7C, left, lanes 17 to
19). Most interestingly, when the 0.3 M
RNA affinity column fraction of
the WERI extract was used, virtually
no repression of splicing was
observed (lanes 11 to 13). Thus,
the presence of other factors in the
0.3 M fraction may further
reduce the repressor activity of
nPTB.
Control introns from adenovirus and

-globin were unaffected by
either nPTB or PTB or by the column fractions, indicating
the
specificity of nPTB and PTB for the
src substrate (Fig.
7B
and data not shown). Moreover, the inhibitory effect of PTB and
nPTB
required the CU element containing sequences upstream of
the N1 exon,
since the BS27 RNA was only weakly repressed by the
PTB fraction and
not at all repressed by nPTB (Fig.
7C, left,
lanes 1 to
8).
The amounts of PTB and nPTB used in these experiments were carefully
measured to ensure that equal amounts of protein were
added in each of
the titrations. These fractions also have equal
binding activity for
the N1 3' splice site, as shown below. To
further ensure that the
observed difference in repression activity
was not due to variations in
our preparation of the proteins,
we repeated these experiments with
several independently isolated
samples of PTB and nPTB and with two
preparations of WERI extract.
The results were always the same; PTB
strongly repressed splicing,
while nPTB only partially reduced the
second-step products. Another
titration of PTB and nPTB into a
different sample of WERI extract
is shown in Fig.
7C
(right).
Assembly of the DCS complex from purified components.
Three
sequence elements were defined previously in functional assays and are
defined here as binding sites for particular proteins: the G tract, the
CU tract, and the UGCAUG element. These three elements all
reside within a 20-nt portion of the DCS sequence. The RNA contacts of
an RRM or a KH domain can be between 4 and 7 nt, making these elements
reasonable binding sites for individual RNA binding proteins (43,
76). However, one imagines that there must be extensive
protein-protein contacts between the DCS complex proteins if they are
simultaneously bound to this short sequence. To examine how the binding
of each DCS protein affected the binding of the others, we performed
gel shift experiments using recombinant or purified fractions of the
individual proteins.
First, we tested whether nPTB and PTB were distinguishable in their
binding properties. Purified nPTB and PTB were used in
electrophoretic
mobility shift assays with both the DCS RNA and
the polypyrimidine
tract of the N1 3' splice site as probes (Fig.
8A, right and left panels, respectively).
Both proteins bound
the 3' splice site RNA, with saturation reached at
the same concentration
of protein, although the mobilities of the PTB
and nPTB complexes
were slightly different. In contrast, with the DCS
RNA probe,
nPTB formed a larger and more abundant complex than PTB did.
In
the PTB binding reaction, the predominant RNA-protein complex
was
much faster migrating and only weakly present in the nPTB
reaction. The
overall binding of the two proteins to the DCS RNA
sequence was much
weaker than that to the 3' splice site. Nevertheless,
the affinity of
nPTB for the DCS RNA probe was clearly higher
than that of PTB.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 8.
Binding of purified nPTB and PTB to the src
N1 exon splicing-regulatory elements in the presence and absence of
other protein components of the DCS complex. (A) The left panel shows a
gel mobility shift analysis of nPTB (lanes 2 to 6) or PTB (lanes 7 to
11) complexed with an N1 3' splice site polypyrimidine tract RNA. Lane
1 contains free RNA probe (20 fmol, 105 cpm). Lanes 2 to 6 contain 50, 100, 200, 400, and 800 ng of purified nPTB. Lanes 7 to 11 contain equivalent amounts of PTB. The right panel shows a gel mobility
shift analysis of nPTB (lanes 2 to 6) or PTB (lanes 7 to 11) complexed
with an src DCS RNA. The amount of protein in each lane is
equivalent to that in the left panel. (B) The left panel shows that
hnRNP H enhances PTB and nPTB binding to the DCS RNA. Binding-reaction
mixtures contained 100 ng of either nPTB (lanes 1 to 5) or PTB (lanes 6 to 10). This was supplemented with 25 ng (lanes 1 and 6), 50 ng (lanes
2 and 7), 100 ng (lanes 3 and 8), 200 ng (lanes 4 and 9), or 400 ng
(lanes 5 and 10) of hnRNP H. The right panel shows assembly of the
DCS-like complex from purified and recombinant factors. A total of 800 ng of purified nPTB, 300 ng of recombinant hnRNP H, and/or 400 ng of a
KSRP-FBP fraction were used where indicated by +. (C) DCS RNA mutants
used in the gel shift experiments. The sequence of the original DCS
probe is shown at the top. The WTs probe sequence is truncated as
indicated. The GTrs, CUTrs, and GCA mutations are indicated.
Gel mobility shift analysis of nPTB complexed with src DCS
RNA mutants in the presence of hnRNP H, KSRP, and FBP is shown below
the sequences. A total of 200 ng of purified nPTB, 300 ng of
recombinant hnRNP H, and/or 400 ng of a KSRP-FBP fraction were used
where indicated by +. The WTs and mutant probes are indicated above.
The position of each complex is shown by an arrow.
|
|
Next, we examined the effect of recombinant hnRNP H on the binding of
nPTB and PTB. hnRNP H interacted very weakly with the
DCS RNA by itself
(Fig.
8B, right, lane 2). However, the effect
of combining the proteins
was striking; binding of both nPTB and
PTB was improved by hnRNP H
(Fig.
8B, left). Complex formation
in the presence of 300 ng of
nPTB and 400 ng of hnRNP H was 4-
to 10-fold higher than for
either protein alone (Fig.
8B, right,
lane 4). Oddly, the gel mobility
of the complex formed with the
combination of hnRNP H and nPTB
was similar to that formed with
nPTB alone (see below). hnRNP H also
stimulated PTB binding, although
equivalent reactions with PTB and
hnRNP H exhibited at least fourfold
less complex formation than with
nPTB at all points in the titration
(Fig.
8B, left). From these
results, it is clear that hnRNP H
strongly affects both nPTB and PTB
binding to the DCS
RNA.
A purified fraction containing almost exclusively KSRP and FBP did not
give an observable complex with the DCS RNA in the
gel shift assay
(Fig.
8B, right, lane 3). Similarly, combining
the KSRP fraction with
hnRNP H gave only a weak new complex (lane
5). This KSRP fraction, when
added to a complex containing both
hnRNP H and nPTB, bound strongly to
the DCS RNA (lane 6). The
mobility of this hnRNP H-nPTB-KSRP complex
was lower than that
of the hnRNP H-nPTB complex and about equivalent to
that of the
complex formed in the crude ASP40 fraction (lane
7).
These gel shift experiments with purified proteins indicate that nPTB
and/or PTB are essential for the cooperative assembly
of hnRNP H and
KSRP into the RNP complex. However, the comigration
of the hnRNP H-nPTB
complex with the complex formed with nPTB
alone was confusing. A
combination of cross-linking and antibody
supershift experiments
indicated that both proteins were indeed
in the hnRNP H-nPTB complex
(data not shown). The comigration
was thus apparently due to a change
in the stoichiometry or conformation
of the nPTB complex upon addition
of H. In addition to the CU
tract, the DCS RNA used for these
experiments has a second potential
PTB binding site. This is a group of
pyrimidine residues at the
extreme 3' end of the DCS RNA that were
known to affect PTB binding
in the RNA affinity chromatography assay
(data not shown). To
resolve the nPTB and hnRNP H-nPTB complexes, we
shortened the
DCS probe to remove these residues (Fig.
8C, top, probe
WTs).
With this WTs probe, nPTB gives a weak complex on its own (Fig.
8C, lane 3). hnRNP H alone gave a faster-migrating complex that
was
barely detectable (lane 2). The combination of these two proteins
allowed the formation of a strong RNP complex band that was larger
than
that of either protein alone, as well as a weak band still
higher in
the gel (lane 4). Finally, the addition of KSRP and
FBP shifted the
nPTB-hnRNP H complex higher in the gel to make
a three-protein DCS
complex (lane
5).
The resolution of the nPTB and hnRNP H-nPTB complexes allowed us to
examine the importance of the different sequence elements
in the
binding of each protein, using the gel shift assay. These
results
agreed well with the cross-linking and affinity chromatography
results.
Mutation of the G tract eliminated the weak binding of
hnRNP H, as
expected (Fig.
8C, lane 7). Interestingly, this mutation
stimulated
nPTB binding (compare lane 8 with lane 3). The DCS
sequence can form a
secondary structure that pairs the G tract
with the CU tract. Mutation
of the G tract presumably allows easier
access of nPTB to the CU
element by disrupting this RNA structure.
This may be part of the
stimulatory activity of hnRNP H for nPTB
binding; by binding to the G
tract, hnRNP H may make the nPTB
site more accessible. The addition of
hnRNP H to the DCS with
a mutant G tract did not further stimulate nPTB
binding, although
a faint higher-molecular-weight complex was seen
(lane 9). The
addition of KSRP and FBP shifted the PTB complex further,
although
this complex was smeared and was apparently less stable than
the
hnRNP H-nPTB-KSRP complex seen on wild-type RNA (lane
10).
Mutation of the CU tract also disrupted the potential secondary
structure between this element and the G tract. However, the
binding of
hnRNP H was only weakly stimulated by this change (lane
12).
Presumably, hnRNP H needs nPTB to bind well, whether the
secondary
structure is there or not. As expected, the CU tract
mutation nearly
eliminated nPTB binding (lane 13). Interestingly,
the combination of
hnRNP H and nPTB gave some complexes with this
RNA (lane 14). These
ranged in mobility from the size of hnRNP
H alone to the size of the
full DCS complex. It is possible that
the interaction between nPTB and
hnRNP H stimulates binding even
if not all the normal RNA contacts can
be made to the mutant RNA.
These hnRNP H-nPTB complexes coalesced into
a strong DCS complex
in the presence of KSRP (lane
15).
Mutation of the UGCAUG element also behaved as predicted.
PTB formed a complex on its own (lane 18). This was shifted to an
hnRNP
H-nPTB complex when hnRNP H was added, although the stimulation
of
binding was not as strong as that seen with the wild-type RNA
(lane
19). Most significantly, the UGCAUG is essential to KSRP
binding, since the hnRNP H-nPTB complex did not show a substantial
further shift in the presence of KSRP (lane
20).
Taken together, the binding data provide a consistent picture of the
DCS complex (Fig.
9). This complex is
held together by
both protein-RNA contacts and protein-protein
contacts. The G
tract is the binding site for hnRNP H and F, although
it is not
clear yet whether hnRNP H and F are in separate complexes or
bind
as a heterodimer (
16). nPTB binds to the CU tract, and
this
interaction is critical in stimulating the subsequent assembly
of
the other proteins. Finally, KSRP and FBP bind to the UGCAUG
element, although, again, these two proteins may bind separately
or together.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 9.
Diagram of the DCS RNP complex. The position of each
protein along the DCS RNA is indicated. These contacts are supported by
cross-linking, affinity chromatography, and gel shift assays using
wild-type and mutant DCS RNA sequences. Homologous pairs of proteins
are indicated (hnRNPs H and F, PTB and nPTB, and KSRP and FBP). The
stoichiometry of hnRNP F and FBP binding relative to their homologs is
not yet known.
|
|
 |
DISCUSSION |
Cooperative assembly of an hnRNP complex.
The regulation of
spliceosome assembly is generally thought to occur within the hnRNP
complexes that assemble onto nascent pre-mRNAs as they are synthesized
by RNAP II. The structures of these pre-mRNPs are extremely complex,
with dozens of different hnRNPs binding to each RNA transcript (4,
42, 52). However, the interactions of these proteins with the RNA
and each other are generally unknown. In this study, we have
characterized the assembly of a small subset of these RNPs that bind to
an important splicing regulatory region in the src pre-mRNA,
the DCS. The DCS is interesting because it can have both enhancing and
repressing activity on the splicing of an upstream exon, depending on
the cellular environment and its adjacent sequences (55,
56).
The c-
src N1 exon is controlled by an intricate combination
of positive and negative regulatory elements that bind to an array
of
RNA binding proteins (
13,
16,
53-56). The role of each DCS
binding protein in splicing regulation is not yet understood.
Individual proteins could be involved in splicing repression and
derepression as well as in true splicing enhancement. Better functional
data on all the DCS binding proteins are needed to resolve their
activities. As we build up our picture of the RNP structure of
the
enhancer region and examine how it changes upon splicing activation,
the roles of the individual proteins should become clearer. With
this
in mind, we examined how the DCS complex assembles from individual
pre-mRNA binding proteins and identified the RNA binding sites
for
several of its
components.
The highly related hnRNP H and F both bind to a GGGGGCUG
element within the DCS. This element is important for
src splicing
enhancer function in vivo, and similar elements
have been identified
in other splicing enhancers (
9,
23,
56,
67). hnRNP H
has also been implicated as a negative regulator of
tropomyosin
splicing (
14). The binding of hnRNP H and F to
this element
is consistent with the known high affinity of these
proteins for
poly(G) resin (
49). Interestingly, although it
is present in
both extracts, hnRNP F is seen cross-linking to the DCS
RNA only
in WERI extract. It is tempting to speculate that this is due
to a preferred interaction of hnRNP F with nPTB over PTB, but
this has
not yet been
shown.
KSRP and FBP interact with the UGCAUG element in the DCS.
This is the most important element in the function of the
c-
src enhancer in vivo and has been found in other splicing
enhancers
(
34,
36,
37,
40,
44). KSRP apparently requires
adjacent
nPTB binding for stable binding to the UGCAUG. In
other systems,
there are UGCAUG elements that function as
enhancers but do not
have apparent adjacent PTB binding sites. Thus,
either KSRP can
cooperate with other adjacent proteins or it may not be
the protein
that mediates the enhancement effect of this element. KSRP
and
FBP also bind extremely tightly to poly(U) resin (
54)
and also
bind to the single-stranded form of a DNA sequence element in
the c-
myc promoter (
18,
20,
21). In this last
capacity,
these proteins have been implicated in the regulation of
transcription,
although this is probably a separate function from that
studied
here (
33). There are additional copies of the hnRNP
H and KSRP
binding elements in the enhancer region surrounding the DCS.
Thus,
the larger enhancer RNP complexes are likely to have multiple
copies of these proteins engaging in numerous cooperative
interactions.
PTB and nPTB both bind to the CUCUCU element of the DCS,
although with different apparent affinities. Of all the DCS binding
proteins, PTB is the factor most strongly implicated in splicing
regulation; PTB is required to repress splicing in nonneural extracts
(
13,
17). In HeLa extract, PTB binds to sites upstream and
downstream of the exon, including the site in the DCS (
13,
17).
Examination of PTB binding to the full-length transcript in
the
HeLa extract indicates that cross-linking of PTB to the upstream
CUCUCU elements requires intact downstream elements. This
implies
cooperation between the PTBs bound at the different elements
(
17).
Here we see binding of PTB and nPTB to the upstream
sites alone
and weak binding to the DCS alone. This may reflect a more
sensitive
binding assay or differences between the short RNAs used here
and the full-length transcript. In WERI extract, where splicing
is
derepressed, PTB and nPTB bind to the pre-mRNA but are removed
from the
upstream sites in an ATP-dependent process (
17). The
downstream protein remains bound under these conditions. We show
here
that this downstream protein is nPTB rather than PTB and
that nPTB is a
key protein in the assembly of the DCS complex
in WERI extract. The
adjacent hnRNP H and KSRP binding sites may
stabilize the nPTB and
prevent its removal from the DCS when it
is lost from the 3' splice
site.
A new tissue-specific RNA binding protein.
We identified and
cloned nPTB as a component of the DCS complex. nPTB is highly related
to PTB/hnRNP I, but where PTB is broadly expressed, nPTB is enriched in
the brain. In WERI-1 cell extracts, both nPTB and PTB are present.
Although PTB and nPTB both bind to the CUCUCU repressor
elements, there are differences in their binding. Both proteins bind
well to the upstream polypyrimidine tract containing two CUCUCU
elements. The DCS portion of the downstream splicing enhancer
contains one repressor element surrounded by the GGGGG and UGCAUG
elements implicated in the positive control of splicing. Both
PTB
and nPTB bind to this sequence on an RNA affinity column.
However, by
gel shift analysis, nPTB shows significantly better
binding to the DCS
sequence than PTB does. This difference is
enhanced by the presence of
a second DCS binding protein, hnRNP
H. These results resolve a mystery
from earlier studies of the
DCS binding proteins: what causes their
tissue-specific assembly?
The DCS RNA assembles into a complex that is
enriched in the WERI
extract. However, the previously identified
components of the
DCS complex are present in both extracts (
16,
53,
54). The
extract specificity of nPTB and its greater affinity
for the DCS
are the likely source of the observed neuron-specific
assembly
of the DCS complex. However, since PTB does bind to the DCS in
other assays, the HeLa extract is likely to form a PTB-DCS complex
that
is just not stable in the gel shift
assay.
The sequence differences between PTB and nPTB should provide clues to
how they differ in activity. PTB and nPTB are most different
in the
long alanine-rich linkers separating RRMs 1 and 2 and RRMs
2 and 3. Interestingly, the linker between RRMs 2 and 3 is also
where the PTB
splice variants are altered (
26). The third RRM
domain of
PTB plays a pivotal role in RNA recognition (
63).
nPTB has a
number of unique residues in this region, including
changes in the loop
between

-strand 1 and

-helix A and the sequence
from helix B
through

-strand 4. In the

-strand 1-helix A loop,
changes from
Glu (nPTB) to Pro (PTB) and Met (nPTB) to Arg (PTB)
could affect RNA
binding specificity, since the corresponding
residues in the U1A RRM
are involved in RNA base recognition (
1,
60). The residues
unique to nPTB within

-strand 4 may also
contribute to the RNA
binding specificity, since their counterparts
in both the Sxl and U1A
proteins make contacts with the RNA (
32,
60). RRM 2 (amino
acids 169 to 264) has been implicated in PTB
homodimer formation and
heterodimer formation with hnRNP L (
30,
59,
63). Most of the
changes in RRM 2 cluster in helix B and
between

-strand 1 and helix
A. According to the solved RRM structures,
helix B is on the opposite
face from the RNA binding surface (
32,
79). If nPTB does not
dimerize with PTB, it will be interesting
to determine whether these
residues affect this
specificity.
Models for splicing derepression.
Because of its extract
specificity and binding properties, nPTB is a prime candidate for
mediating the loss of splicing repression in WERI-1 cells. However,
significant further work is required to prove this. Since nPTB is only
weakly expressed in at least one cell line (LA-N-5) where the N1 exon
is efficiently spliced, nPTB cannot be the sole determinant of N1
splicing. This is not entirely surprising, since previous work has
shown that N1 splicing is controlled by a complex mixture of positive
and negative elements across the region of the exon (55,
56). The inclusion of the exon can be increased by removing one
of its repression mechanisms or by increasing its activation, and
different cells seem to make different use of these mechanisms
(55). The LA-N-5 cells may overcome the repression by PTB
through increased enhancer activity. Indeed, the downstream enhancer is
particularly strong and the repressor is relatively weak in LA-N-5
cells (55).
Without knowing more about how PTB represses splicing, it is difficult
to speculate on whether or how this could be counteracted
by nPTB. One
possibility is that differences in the oligomerization
properties of
PTB and nPTB affect their repression activity. PTB
can exist as a
homodimer in solution (
59,
63). Since the bulk
of nPTB can
be cleanly separated from PTB, it is not clear whether
nPTB is forming
heterodimers with PTB or homodimers with itself.
The ability to form
oligomers may allow PTB to assemble a higher-order
complex on the four
repressor elements surrounding the N1 exon
(
17). The
resulting RNA loop could prevent the assembly of the
spliceosome on the
N1 exon. In neuronal extract, nPTB bound to
the DCS may not stably
interact with either PTB or nPTB bound
to the other elements. This
disruption of bridging between the
CUCUCU elements could
prevent the repression of
splicing.
It is also likely that PTB and nPTB will interact with different sets
of auxiliary factors that modify their behavior. One
indication of this
is that factors in the 0.3 M fraction from
the DCS RNA affinity column
apparently reduce the ability of nPTB
to repress splicing. The
importance of such protein-protein interactions
is also illustrated by
the stimulation of nPTB binding to the
DCS RNA by hnRNP
H.
The Grabowski laboratory also reported a strong correlation between the
binding of a brain-specific form of PTB and the neuron-specific
splicing of exons in the GABA
A receptor

2 subunit, the
NMDA receptor
NR1, and the clathrin light-chain pre-mRNAs (
2,
28,
81).
It seems likely that this rat brain protein is nPTB. In all
three
of these transcripts, a recombinant glutathione
S-transferase-PTB
fusion protein could repress the splicing
of the exons in favor
of the nonneural pathway. nPTB has also been
cloned in a yeast
two-hybrid screen as interacting with the Nova
protein, a putative
splicing regulator that is highly neuron specific
(
6,
38,
64). Nova is present in WERI extract but does not
seem to affect
N1 splicing (
38) (V. Markovtsov, unpublished
data). Nevertheless,
it will be interesting to determine the relative
affinities of
PTB and nPTB for Nova, since it is a good example of the
type
of protein that may cooperate with nPTB in its function. Thus,
nPTB is a potential player in the regulation of many different
neural
splicing systems. An important problem for the future will
be
understanding what happens after regulatory proteins bind to
the
pre-mRNA and filling the current gap between proteins in the
DCS
complex or other hnRNP complexes and the general splicing
machinery.
 |
ACKNOWLEDGMENTS |
We thank Adrian Krainer, Philippe Bouvet, David Levens, Gideon
Dreyfuss, Joan Steitz, Mark Roth, and Karla Neugebauer for providing
antibodies and Hosung Min for providing the WERI-1 cDNA library. We
thank Chris Smith, Charles Query, Jane Wu, Frederic Allain, and members
of the Black laboratory for critical evaluation of the manuscript. We
are particularly grateful to Robert Darnell and Valery Bliskovsky for
communicating unpublished results and to Ray Chan for advice on protein purification.
This work was supported by NIH grant R01 GM49662 to D.L.B. V.M. is
supported by a fellowship from the Jane Coffin Childs Memorial Fund for
Medical Research. D.L.B. is an associate investigator of the Howard
Hughes Medical Institute and a David and Lucile Packard Foundation Fellow.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 5-748 MRL, Box
951662, 675 Charles E. Young Dr. South, Los Angeles, CA 90095-1662. Phone: (310) 794-7644. Fax: (310) 206-8623. E-mail:
DougB{at}microbio.lifesci.ucla.edu.
 |
REFERENCES |
| 1.
|
Allain, F. H.,
C. C. Gubser,
P. W. Howe,
K. Nagai,
D. Neuhaus, and G. Varani.
1996.
Specificity of ribonucleoprotein interaction determined by RNA folding during complex formulation.
Nature
380:646-650[CrossRef][Medline].
|
| 2.
|
Ashiya, M., and P. J. Grabowski.
1997.
A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart.
RNA
3:996-1015[Abstract].
|
| 3.
|
Bai, Y.,
D. Lee,
T. Yu, and L. A. Chasin.
1999.
Control of 3' splice site choice in vivo by ASF/SF2 and hnRNP A1.
Nucleic Acids Res.
27:1126-1134[Abstract/Free Full Text].
|
| 4.
|
Bennett, M.,
S. Piñol-Roma,
D. Staknis,
G. Dreyfuss, and R. Reed.
1992.
Differential binding of heterogeneous nuclear ribonucleoproteins to mRNA precursors prior to spliceosome assembly in vitro.
Mol. Cell. Biol.
12:3165-3175[Abstract/Free Full Text].
|
| 5.
|
Black, D. L.
1992.
Activation of c-src neuron-specific splicing by an unusual RNA element in vivo and in vitro.
Cell.
69:795-807[CrossRef][Medline].
|
| 6.
|
Buckanovich, R. J.,
J. B. Posner, and R. B. Darnell.
1993.
Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system.
Neuron
11:657-672[CrossRef][Medline].
|
| 7.
|
Caceres, J. F., and A. R. Krainer.
1997.
Mammalian pre-mRNA splicing factors, p. 174-217.
In
A. R. Krainer (ed.), Eukaryotic mRNA processing. Oxford University Press, Oxford, United Kingdom.
|
| 8.
|
Caputi, M.,
A. Mayeda,
A. R. Krainer, and A. M. Zahler.
1999.
hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing.
EMBO J.
18:4060-4067[CrossRef][Medline].
|
| 9.
|
Carlo, T.,
D. A. Sterner, and S. M. Berget.
1996.
An intron splicing enhancer containing a G-rich repeat facilitates inclusion of a vertebrate micro-exon.
RNA
2:342-353[Abstract].
|
| 10.
|
Chabot, B.
1996.
Directing alternative splicing: cast and scenarios.
Trends Genet.
12:472-478[CrossRef][Medline].
|
| 11.
|
Chabot, B.,
M. Blanchette,
I. Lapierre, and H. La Branche.
1997.
An intron element modulating 5' splice site selection in the hnRNP A1 pre-mRNA interacts with hnRNP A1.
Mol. Cell. Biol.
17:1776-1786[Abstract].
|
| 12.
|
Chan, R. C., and D. L. Black.
1995.
Conserved intron elements repress splicing of a neuron-specific c-src exon in vitro.
Mol. Cell. Biol.
15:6377-6385[Abstract].
|
| 13.
|
Chan, R. C., and D. L. Black.
1997.
The polypyrimidine tract binding protein binds upstream of neural cell-specific c-src exon N1 to repress the splicing of the intron downstream.
Mol. Cell. Biol.
17:4667-4676[Abstract].
|
| 14.
|
Chen, C. D.,
R. Kobayashi, and D. M. Helfman.
1999.
Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene.
Genes Dev.
13:593-606[Abstract/Free Full Text].
|
| 15.
|
Chomczynsky, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidine thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 16.
|
Chou, M. Y.,
N. Rooke,
C. W. Turck, and D. L. Black.
1999.
hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells.
Mol. Cell. Biol.
19:69-77[Abstract/Free Full Text].
|
| 17.
|
Chou, M. Y.,
J. U. Underwood,
J. Nikolic,
M. H. T. Luu, and D. L. Black.
2000.
Multisite binding and release of polypyrimidine tract binding protein during the regulation of c-src neural specific splicing.
Mol. Cell
5:949-957[CrossRef][Medline].
|
| 18.
|
Davis-Smyth, T.,
R. C. Duncan,
T. Zheng,
G. Michelotti, and D. Levens.
1996.
The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators.
J. Biol. Chem.
271:31679-31687[Abstract/Free Full Text].
|
| 19.
|
Dreyfuss, G.,
M. J. Matunis,
S. Piñol-Roma, and C. G. Burd.
1993.
hnRNP proteins and the biogenesis of mRNA.
Annu. Rev. Biochem.
62:289-321[CrossRef][Medline].
|
| 20.
|
Duncan, R.,
L. Bazar,
G. Michelotti,
T. Tomonaga,
H. Krutzsch,
M. Avigan, and D. Levens.
1994.
A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif.
Genes Dev.
8:465-480[Abstract/Free Full Text].
|
| 21.
|
Duncan, R.,
I. Collins,
T. Tomonaga,
T. Zhang, and D. Levens.
1996.
A unique transactivation sequence motif is found in the carboxyl-terminal domain of the single-strand-binding protein FBP.
Mol. Cell. Biol.
16:2274-2282[Abstract].
|
| 22.
|
Fan, H.,
J. L. Goodier,
J. R. Chamberlain,
D. R. Engelke, and R. J. Maraia.
1998.
5' processing of tRNA precursors can be modulated by the human La antigen phosphoprotein.
Mol. Cell. Biol.
18:3201-3211[Abstract/Free Full Text].
|
| 23.
|
Gallego, M. E.,
P. Sirand-Pugnet,
P. Durosay,
B. Clouet d'Orval,
Y. d'Aubenton-Carafa,
E. Brody,
A. Expert-Bezancon, and J. Marie.
1996.
Tissue-specific splicing of two mutually exclusive exons of the chicken beta-tropomyosin pre-mRNA: positive and negative regulations.
Biochimie
78:457-465[Medline].
|
| 24.
|
Ghetti, A.,
S. Pinol-Roma,
W. M. Michael,
C. Morandi, and G. Dreyfuss.
1992.
hnRNP I, the polypyrimidine tract-binding protein: distinct nuclear localization and association with hnRNAs.
Nucleic Acids Res.
20:3671-3678[Abstract/Free Full Text].
|
| 25.
|
Ghisolfi-Nieto, L.,
G. Joseph,
F. Puvion-Dutilleul,
F. Amalric, and P. Bouvet.
1996.
Nucleolin is a sequence-specific RNA-binding protein: characterization of targets on pre-ribosomal RNA.
J. Mol. Biol.
260:34-53[CrossRef][Medline].
|
| 26.
|
Gil, A.,
P. A. Sharp,
S. F. Jamison, and M. A. Garcia-Blanco.
1991.
Characterization of cDNAs encoding the polypyrimidine tract-binding protein.
Genes Dev.
5:1224-1236[Abstract/Free Full Text].
|
| 27.
|
Gooding, C.,
G. C. Roberts, and C. W. Smith.
1998.
Role of an inhibitory pyrimidine element and polypyrimidine tract binding protein in repression of a regulated alpha-tropomyosin exon.
RNA
4:85-100[Abstract].
|
| 28.
|
Grabowski, P. J.
1998.
Splicing regulation in neurons: tinkering with cell-specific control.
Cell
92:709-712[CrossRef][Medline].
|
| 29.
|
Grossman, J. S.,
M. I. Meyer,
Y. C. Wang,
G. J. Mulligan,
R. Kobayashi, and D. M. Helfman.
1998.
The use of antibodies to the polypyrimidine tract binding protein (PTB) to analyze the protein components that assemble on alternatively spliced pre-mRNAs that use distant branch points.
RNA
4:613-625[Abstract].
|
| 30.
|
Hahm, B.,
O. H. Cho,
J. E. Kim,
Y. K. Kim,
J. H. Kim,
Y. L. Oh, and S. K. Jang.
1998.
Polypyrimidine tract-binding protein interacts with HnRNP L.
FEBS Lett.
425:401-406[CrossRef][Medline].
|
| 31.
|
Hanamura, A.,
J. F. Caceres,
A. Mayeda,
B. R. Franza, Jr., and A. R. Krainer.
1998.
Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors.
RNA
4:430-444[Abstract].
|
| 32.
|
Handa, N.,
O. Nureki,
K. Kurimoto,
I. Kim,
H. Sakamoto,
Y. Shimura,
Y. Muto, and S. Yokoyama.
1999.
Structural basis for recognition of the tra mRNA precursor by the Sex-lethal protein.
Nature
398:579-585[CrossRef][Medline].
|
| 33.
|
He, L.,
J. Liu,
I. Collins,
S. Sanford,
B. O'Connell,
C. J. Benham, and D. Levens.
2000.
Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression.
EMBO J.
19:1034-1044[CrossRef][Medline].
|
| 34.
|
Hedjran, F.,
J. M. Yeakley,
G. S. Huh,
R. O. Hynes, and M. G. Rosenfeld.
1997.
Control of alternative pre-mRNA splicing by distributed pentameric repeats.
Proc. Natl. Acad. Sci. USA
94:12343-12347[Abstract/Free Full Text].
|
| 35.
|
Hertel, K. J., and T. Maniatis.
1998.
The function of multisite splicing enhancers.
Mol. Cell
1:449-455[CrossRef][Medline].
|
| 36.
|
Huh, G. S., and R. O. Hynes.
1993.
Elements regulating an alternatively spliced exon of the rat fibronectin gene.
Mol. Cell. Biol.
13:5301-5314[Abstract/Free Full Text].
|
| 37.
|
Huh, G. S., and R. O. Hynes.
1994.
Regulation of alternative pre-mRNA splicing by a novel repeated hexanucleotide element.
Genes Dev.
8:1561-1574[Abstract/Free Full Text].
|
| 38.
|
Jensen, K. B.,
B. K. Dredge,
G. Stefani,
R. Zhong,
R. J. Buckanovich,
H. J. Okano,
Y. Y. Yang, and R. B. Darnell.
2000.
Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability.
Neuron
25:359-371[CrossRef][Medline].
|
| 39.
|
Kamma, H.,
D. S. Portman, and G. Dreyfuss.
1995.
Cell type-specific expression of hnRNP proteins.
Exp. Cell Res.
221:187-196[CrossRef][Medline].
|
| 40.
|
Kawamoto, S.
1996.
Neuron-specific alternative splicing of nonmuscle myosin II heavy chain-B pre-mRNA requires a cis-acting intron sequence.
J. Biol. Chem.
271:17613-17616[Abstract/Free Full Text].
|
| 41.
|
Krainer, A. R.,
T. Maniatis,
B. Ruskin, and M. R. Green.
1984.
Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro.
Cell
36:993-1005[CrossRef][Medline].
|
| 42.
|
Krecic, A. M., and M. S. Swanson.
1999.
hnRNP complexes: composition, structure, and function.
Curr. Opin. Cell Biol.
11:363-371[CrossRef][Medline].
|
| 43.
|
Lewis, H. A.,
K. Musunuru,
K. B. Jensen,
C. Edo,
H. Chen,
R. B. Darnell, and S. K. Burley.
2000.
Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome.
Cell
100:323-332[CrossRef][Medline].
|
| 44.
|
Lim, L. P., and P. A. Sharp.
1998.
Alternative splicing of the fibronectin EIIIB exon depends on specific TGCATG repeats.
Mol. Cell. Biol.
18:3900-3906[Abstract/Free Full Text].
|
| 45.
|
Lin, C. H., and J. G. Patton.
1995.
Regulation of alternative 3' splice site selection by constitutive splicing factors.
RNA
1:234-245[Abstract].
|
| 46.
|
Lopez, A. J.
1998.
Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation.
Annu. Rev. Genet.
32:279-305[CrossRef][Medline].
|
| 47.
|
Manley, J. L., and R. Tacke.
1996.
SR proteins and splicing control.
Genes Dev.
10:1569-1579[Free Full Text].
|
| 48.
|
Markovtsov, V.,
A. Mustaev, and A. Goldfarb.
1996.
Protein-RNA interactions in the active center of transcription elongation complex.
Proc. Natl. Acad. Sci. USA
93:3221-3226[Abstract/Free Full Text].
|
| 49.
|
Matunis, M. J.,
J. Xing, and G. Dreyfuss.
1994.
The hnRNP F protein: unique primary structure, nucleic acid-binding properties, and subcellular localization.
Nucleic Acids Res.
22:1059-1067[Abstract/Free Full Text].
|
| 50.
|
Mayeda, A.,
D. M. Helfman, and A. R. Krainer.
1993.
Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF.
Mol. Cell. Biol.
13:2993-3001[Abstract/Free Full Text].
|
| 51.
|
Mayeda, A., and A. R. Krainer.
1992.
Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2.
Cell
68:365-375[CrossRef][Medline].
|
| 52.
|
McAffee, J. G.,
M. Huang,
S. Soltaninassab,
J. E. Rech,
S. Iyengar, and W. M. Lestourgeon.
1997.
The packaging of pre-mRNA, p. 68-102.
In
A. Krainer (ed.), Eukaryotic mRNA processing. Oxford University Press, Oxford, United Kingdom.
|
| 53.
|
Min, H.,
R. C. Chan, and D. L. Black.
1995.
The generally expressed hnRNP F is involved in a neural-specific pre-mRNA splicing event.
Genes Dev.
9:2659-2671[Abstract/Free Full Text].
|
| 54.
|
Min, H.,
C. W. Turck,
J. M. Nikolic, and D. L. Black.
1997.
A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer.
Genes Dev.
11:1023-1036[Abstract/Free Full Text].
|
| 55.
|
Modafferi, E. F., and D. L. Black.
1999.
Combinatorial control of a neuron-specific exon.
RNA
5:687-706[Abstract].
|
| 56.
|
Modafferi, E. F., and D. L. Black.
1997.
A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon.
Mol. Cell. Biol.
17:6537-6545[Abstract].
|
| 57.
|
Mulligan, G. J.,
W. Guo,
S. Wormsley, and D. M. Helfman.
1992.
Polypyrimidine tract binding protein interacts with sequences involved in alternative splicing of beta-tropomyosin pre-mRNA.
J. Biol. Chem.
267:25480-25487[Abstract/Free Full Text].
|
| 58.
|
Nudler, E.,
E. Avetissova,
V. Markovtsov, and A. Goldfarb.
1996.
Transcription processivity: protein-DNA interactions holding together the elongation complex.
Science
273:211-217[Abstract].
|
| 59.
|
Oh, Y. L.,
B. Hahm,
Y. K. Kim,
H. K. Lee,
J. W. Lee,
O. Song,
K. Tsukiyama-Kohara,
M. Kohara,
A. Nomoto, and S. K. Jang.
1998.
Determination of functional domains in polypyrimidine-tract-binding protein.
Biochem. J.
331:169-175.
|
| 60.
|
Oubridge, C.,
N. Ito,
P. R. Evans,
C. H. Teo, and K. Nagai.
1994.
Crystal structure at 1.92 A resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin.
Nature
372:432-438[CrossRef][Medline].
|
| 61.
|
Patton, J. G.,
S. A. Mayer,
P. Tempst, and B. Nadal-Ginard.
1991.
Characterization and molecular cloning of polypyrimidine tract-binding protein: a component of a complex necessary for pre-mRNA splicing.
Genes Dev.
5:1237-1251[Abstract/Free Full Text].
|
| 62.
|
Perez, I.,
C. H. Lin,
J. G. McAfee, and J. G. Patton.
1997.
Mutation of PTB binding sites causes misregulation of alternative 3' splice site selection in vivo.
RNA
3:764-778[Abstract].
|
| 63.
|
Pérez, I.,
J. G. McAfee, and J. G. Patton.
1997.
Multiple RRMs contribute to RNA binding specificity and affinity for polypyrimidine tract binding protein.
Biochemistry
36:11881-11890[CrossRef][Medline].
|
| 64.
|
Polydorides, A. D.,
H. J. Okana,
Y. Y. L. Yang,
G. Stefani, and R. B. Darnell.
2000.
A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing.
Proc. Natl. Acad. Sci. USA
97:6350-6355[Abstract/Free Full Text].
|
| 65.
|
Singh, R.,
J. Valcarcel, and M. R. Green.
1995.
Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins.
Science
268:1173-1176[Abstract/Free Full Text].
|
| 66.
|
Siomi, H., and G. Dreyfuss.
1997.
RNA-binding proteins as regulators of gene expression.
Curr. Opin. Genet. Dev.
7:345-353[CrossRef][Medline].
|
| 67.
|
Sirand-Pugnet, P.,
P. Durosay,
E. Brody, and J. Marie.
1995.
An intronic (A/U)GGG repeat enhances the splicing of an alternative intron of the chicken beta-tropomyosin pre-mRNA.
Nucleic Acids Res.
23:3501-3507[Abstract/Free Full Text].
|
| 68.
|
Solnick, D.
1985.
Trans splicing of mRNA precursors.
Cell
42:157-164[CrossRef][Medline].
|
| 69.
|
Soltaninassab, S. R.,
J. G. McAfee,
L. Shahied-Milam, and W. M. LeStourgeon.
1998.
Oligonucleotide binding specificities of the hnRNP C protein tetramer.
Nucleic Acids Res.
26:3410-3417[Abstract/Free Full Text].
|
| 70.
|
Stefano, J. E.
1984.
Purified lupus antigen La recognizes an oligouridylate stretch common to the 3' termini of RNA polymerase III transcripts.
Cell
36:145-154[CrossRef][Medline].
|
| 71.
|
Sugrue, M. M.,
J. S. Brugge,
D. R. Marshak,
P. Greengard, and E. L. Gustafson.
1990.
Immunocytochemical localization of the neuron-specific form of the c-src gene product, pp60c-src(+), in rat brain.
J. Neurosci.
10:2513-2527[Abstract].
|
| 72.
|
Swanson, M. S., and G. Dreyfuss.
1988.
Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities.
Mol. Cell. Biol.
8:2237-2241[Abstract/Free Full Text].
|
| 73.
|
Swanson, M. S., and G. Dreyfuss.
1988.
RNA binding specificity of hnRNP proteins: a subset bind to the 3' end of introns.
EMBO J.
7:3519-3529[Medline].
|
| 74.
|
Valcarcel, J., and F. Gebauer.
1997.
Post-transcriptional regulation: the dawn of PTB.
Curr. Biol.
7:R705-R708[CrossRef][Medline].
|
| 75.
|
Valcarcel, J., and M. R. Green.
1996.
The SR protein family: pleiotropic functions in pre-mRNA splicing.
Trends Biochem. Sci.
21:296-301[CrossRef][Medline].
|
| 76.
|
Varani, G., and K. Nagai.
1998.
RNA recognition by RNP proteins during RNA processing.
Annu. Rev. Biophys. Biomol. Struct.
27:407-445[CrossRef][Medline].
|
| 77.
|
Wang, J., and J. L. Manley.
1997.
Regulation of pre-mRNA splicing in metazoa.
Curr. Opin. Genet. Dev.
7:205-211[CrossRef][Medline].
|
| 78.
|
Wang, Y.-C.,
M. Selvakumar, and D. Helfman.
1997.
Alternative pre-mRNA splicing, p. 242-279.
In
A. R. Krainer (ed.), Eukaryotic mRNA processing. Oxford University Press, Oxford, United Kingdom.
|
| 79.
|
Xu, R. M.,
L. Jokhan,
X. Cheng,
A. Mayeda, and A. R. Krainer.
1997.
Crystal structure of human UP1, the domain of hnRNP A1 that contains two RNA-recognition motifs.
Structure
5:559-570[Medline].
|
| 80.
|
Yamamoto, H.,
K. Tsukahara,
Y. Kanaoka,
S. Jinno, and H. Okayama.
1999.
Isolation of a mammalian homologue of a fission yeast differentiation regulator.
Mol. Cell. Biol.
19:3829-3841[Abstract/Free Full Text].
|
| 81.
|
Zhang, L.,
W. Liu, and P. J. Grabowski.
1999.
Coordinate repression of a trio of neuron-specific splicing events by the splicing regulator PTB.
RNA
5:117-130[Abstract].
|
Molecular and Cellular Biology, October 2000, p. 7463-7479, Vol. 20, No. 20
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ferrera, L., Caputo, A., Ubby, I., Bussani, E., Zegarra-Moran, O., Ravazzolo, R., Pagani, F., Galietta, L. J. V.
(2009). Regulation of TMEM16A Chloride Channel Properties by Alternative Splicing. J. Biol. Chem.
284: 33360-33368
[Abstract]
[Full Text]
-
Millevoi, S., Decorsiere, A., Loulergue, C., Iacovoni, J., Bernat, S., Antoniou, M., Vagner, S.
(2009). A physical and functional link between splicing factors promotes pre-mRNA 3' end processing. Nucleic Acids Res
37: 4672-4683
[Abstract]
[Full Text]
-
Bian, Y., Masuda, A., Matsuura, T., Ito, M., Okushin, K., Engel, A. G., Ohno, K.
(2009). Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome. Hum Mol Genet
18: 1229-1237
[Abstract]
[Full Text]
-
Coles, J. L., Hallegger, M., Smith, C. W.J.
(2009). A nonsense exon in the Tpm1 gene is silenced by hnRNP H and F. RNA
15: 33-43
[Abstract]
[Full Text]
-
Xu, M., McCarrey, J. R., Hecht, N. B.
(2008). A cytoplasmic variant of the KH-type splicing regulatory protein serves as a decay-promoting factor for phosphoglycerate kinase 2 mRNA in murine male germ cells. Nucleic Acids Res
36: 7157-7167
[Abstract]
[Full Text]
-
Somberg, M., Zhao, X., Frohlich, M., Evander, M., Schwartz, S.
(2008). Polypyrimidine Tract Binding Protein Induces Human Papillomavirus Type 16 Late Gene Expression by Interfering with Splicing Inhibitory Elements at the Major Late 5' Splice Site, SD3632. J. Virol.
82: 3665-3678
[Abstract]
[Full Text]
-
Zhu, H., Hinman, M. N., Hasman, R. A., Mehta, P., Lou, H.
(2008). Regulation of Neuron-Specific Alternative Splicing of Neurofibromatosis Type 1 Pre-mRNA. Mol. Cell. Biol.
28: 1240-1251
[Abstract]
[Full Text]
-
David, C. J., Manley, J. L.
(2008). The search for alternative splicing regulators: new approaches offer a path to a splicing code. Genes Dev.
22: 279-285
[Full Text]
-
Lewis, R. A., Gagnon, J. A., Mowry, K. L.
(2008). PTB/hnRNP I Is Required for RNP Remodeling during RNA Localization in Xenopus Oocytes. Mol. Cell. Biol.
28: 678-686
[Abstract]
[Full Text]
-
Novoyatleva, T., Heinrich, B., Tang, Y., Benderska, N., Butchbach, M. E.R., Lorson, C. L., Lorson, M. A., Ben-Dov, C., Fehlbaum, P., Bracco, L., Burghes, A. H.M., Bollen, M., Stamm, S.
(2008). Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet
17: 52-70
[Abstract]
[Full Text]
-
Paradis, C., Cloutier, P., Shkreta, L., Toutant, J., Klarskov, K., Chabot, B.
(2007). hnRNP I/PTB can antagonize the splicing repressor activity of SRp30c. RNA
13: 1287-1300
[Abstract]
[Full Text]
-
Coutinho-Mansfield, G. C., Xue, Y., Zhang, Y., Fu, X.-D.
(2007). PTB/nPTB switch: a post-transcriptional mechanism for programming neuronal differentiation. Genes Dev.
21: 1573-1577
[Full Text]
-
Boutz, P. L., Stoilov, P., Li, Q., Lin, C.-H., Chawla, G., Ostrow, K., Shiue, L., Ares, M. Jr., Black, D. L.
(2007). A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev.
21: 1636-1652
[Abstract]
[Full Text]
-
Wang, E., Dimova, N., Cambi, F.
(2007). PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes. Nucleic Acids Res
0: gkm387v1-15
[Abstract]
[Full Text]
-
Xu, M., Hecht, N. B.
(2007). Polypyrimidine Tract Binding Protein 2 Stabilizes Phosphoglycerate Kinase 2 mRNA in Murine Male Germ Cells by Binding to Its 3'UTR. Biol. Reprod.
76: 1025-1033
[Abstract]
[Full Text]
-
Dalziel, M., Nunes, N. M., Furger, A.
(2007). Two G-Rich Regulatory Elements Located Adjacent to and 440 Nucleotides Downstream of the Core Poly(A) Site of the Intronless Melanocortin Receptor 1 Gene Are Critical for Efficient 3' End Processing. Mol. Cell. Biol.
27: 1568-1580
[Abstract]
[Full Text]
-
Boutz, P. L., Chawla, G., Stoilov, P., Black, D. L.
(2007). MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev.
21: 71-84
[Abstract]
[Full Text]
-
Crawford, J. B., Patton, J. G.
(2006). Activation of {alpha}-Tropomyosin Exon 2 Is Regulated by the SR Protein 9G8 and Heterogeneous Nuclear Ribonucleoproteins H and F. Mol. Cell. Biol.
26: 8791-8802
[Abstract]
[Full Text]
-
Bonano, V. I., Oltean, S., Brazas, R. M., Garcia-Blanco, M. A.
(2006). Imaging the alternative silencing of FGFR2 exon IIIb in vivo. RNA
12: 2073-2079
[Abstract]
[Full Text]
-
Zhu, H., Hasman, R. A., Barron, V. A., Luo, G., Lou, H.
(2006). A Nuclear Function of Hu Proteins as Neuron-specific Alternative RNA Processing Regulators. Mol. Biol. Cell
17: 5105-5114
[Abstract]
[Full Text]
-
Pautz, A., Linker, K., Hubrich, T., Korhonen, R., Altenhofer, S., Kleinert, H.
(2006). The Polypyrimidine Tract-binding Protein (PTB) Is Involved in the Post-transcriptional Regulation of Human Inducible Nitric Oxide Synthase Expression. J. Biol. Chem.
281: 32294-32302
[Abstract]
[Full Text]
-
Iguchi, N., Tobias, J. W., Hecht, N. B.
(2006). Expression profiling reveals meiotic male germ cell mRNAs that are translationally up- and down-regulated. Proc. Natl. Acad. Sci. USA
103: 7712-7717
[Abstract]
[Full Text]
-
Yoshikawa, T., Iwasaki, T., Ida-Hosonuma, M., Yoneyama, M., Fujita, T., Horie, H., Miyazawa, M., Abe, S., Simizu, B., Koike, S.
(2006). Role of the Alpha/Beta Interferon Response in the Acquisition of Susceptibility to Poliovirus by Kidney Cells in Culture. J. Virol.
80: 4313-4325
[Abstract]
[Full Text]
-
CLERTE, C., HALL, K. B.
(2006). Characterization of multimeric complexes formed by the human PTB1 protein on RNA. RNA
12: 457-475
[Abstract]
[Full Text]
-
Underwood, J. G., Boutz, P. L., Dougherty, J. D., Stoilov, P., Black, D. L.
(2005). Homologues of the Caenorhabditis elegans Fox-1 Protein Are Neuronal Splicing Regulators in Mammals. Mol. Cell. Biol.
25: 10005-10016
[Abstract]
[Full Text]
-
Lin, J.-C., Tarn, W.-Y.
(2005). Exon Selection in {alpha}-Tropomyosin mRNA Is Regulated by the Antagonistic Action of RBM4 and PTB. Mol. Cell. Biol.
25: 10111-10121
[Abstract]
[Full Text]
-
Soller, M., White, K.
(2005). ELAV Multimerizes on Conserved AU4-6 Motifs Important for ewg Splicing Regulation. Mol. Cell. Biol.
25: 7580-7591
[Abstract]
[Full Text]
-
Kim, D.-H., Langlois, M.-A., Lee, K.-B., Riggs, A. D., Puymirat, J., Rossi, J. J.
(2005). HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res
33: 3866-3874
[Abstract]
[Full Text]
-
Mitchell, S. A., Spriggs, K. A., Bushell, M., Evans, J. R., Stoneley, M., Le Quesne, J. P.C., Spriggs, R. V., Willis, A. E.
(2005). Identification of a motif that mediates polypyrimidine tract-binding protein-dependent internal ribosome entry. Genes Dev.
19: 1556-1571
[Abstract]
[Full Text]
-
Campbell, S. A., Lin, J., Dobrikova, E. Y., Gromeier, M.
(2005). Genetic Determinants of Cell Type-Specific Poliovirus Propagation in HEK 293 Cells. J. Virol.
79: 6281-6290
[Abstract]
[Full Text]
-
AMIR-AHMADY, B., BOUTZ, P. L., MARKOVTSOV, V., PHILLIPS, M. L., BLACK, D. L.
(2005). Exon repression by polypyrimidine tract binding protein. RNA
11: 699-716
[Abstract]
[Full Text]
-
Nakahata, S., Kawamoto, S.
(2005). Tissue-dependent isoforms of mammalian Fox-1 homologs are associated with tissue-specific splicing activities. Nucleic Acids Res
33: 2078-2089
[Abstract]
[Full Text]
-
Adair, R., Liebisch, G. W., Su, Y., Colberg-Poley, A. M.
(2004). Alteration of cellular RNA splicing and polyadenylation machineries during productive human cytomegalovirus infection. J. Gen. Virol.
85: 3541-3553
[Abstract]
[Full Text]
-
Guest, S., Pilipenko, E., Sharma, K., Chumakov, K., Roos, R. P.
(2004). Molecular Mechanisms of Attenuation of the Sabin Strain of Poliovirus Type 3. J. Virol.
78: 11097-11107
[Abstract]
[Full Text]
-
Expert-Bezancon, A., Sureau, A., Durosay, P., Salesse, R., Groeneveld, H., Lecaer, J. P., Marie, J.
(2004). hnRNP A1 and the SR Proteins ASF/SF2 and SC35 Have Antagonistic Functions in Splicing of {beta}-Tropomyosin Exon 6B. J. Biol. Chem.
279: 38249-38259
[Abstract]
[Full Text]
-
Castelo-Branco, P., Furger, A., Wollerton, M., Smith, C., Moreira, A., Proudfoot, N.
(2004). Polypyrimidine Tract Binding Protein Modulates Efficiency of Polyadenylation. Mol. Cell. Biol.
24: 4174-4183
[Abstract]
[Full Text]
-
SHEN, H., KAN, J. L.C., GHIGNA, C., BIAMONTI, G., GREEN, M. R.
(2004). A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA
10: 787-794
[Abstract]
[Full Text]
-
Lu, J.-Y., Schneider, R. J.
(2004). Tissue Distribution of AU-rich mRNA-binding Proteins Involved in Regulation of mRNA Decay. J. Biol. Chem.
279: 12974-12979
[Abstract]
[Full Text]
-
Xing, Y., Resch, A., Lee, C.
(2004). The Multiassembly Problem: Reconstructing Multiple Transcript Isoforms From EST Fragment Mixtures. Genome Res
14: 426-441
[Abstract]
[Full Text]
-
Hall, M. P., Huang, S., Black, D. L.
(2004). Differentiation-induced Colocalization of the KH-type Splicing Regulatory Protein with Polypyrimidine Tract Binding Protein and the c-src Pre-mRNA. Mol. Biol. Cell
15: 774-786
[Abstract]
[Full Text]
-
Baraniak, A. P., Lasda, E. L., Wagner, E. J., Garcia-Blanco, M. A.
(2003). A Stem Structure in Fibroblast Growth Factor Receptor 2 Transcripts Mediates Cell-Type-Specific Splicing by Approximating Intronic Control Elements. Mol. Cell. Biol.
23: 9327-9337
[Abstract]
[Full Text]
-
Zhu, H., Hasman, R. A., Young, K. M., Kedersha, N. L., Lou, H.
(2003). U1 snRNP-Dependent Function of TIAR in the Regulation of Alternative RNA Processing of the Human Calcitonin/CGRP Pre-mRNA. Mol. Cell. Biol.
23: 5959-5971
[Abstract]
[Full Text]
-
Galiana-Arnoux, D., Lejeune, F., Gesnel, M.-C., Stevenin, J., Breathnach, R., Del Gatto-Konczak, F.
(2003). The CD44 Alternative v9 Exon Contains a Splicing Enhancer Responsive to the SR Proteins 9G8, ASF/SF2, and SRp20. J. Biol. Chem.
278: 32943-32953
[Abstract]
[Full Text]
-
Chandler, D. S., Qi, J., Mattox, W.
(2003). Direct Repression of Splicing by transformer-2. Mol. Cell. Biol.
23: 5174-5185
[Abstract]
[Full Text]
-
Xie, J., Lee, J.-A., Kress, T. L., Mowry, K. L., Black, D. L.
(2003). Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein. Proc. Natl. Acad. Sci. USA
100: 8776-8781
[Abstract]
[Full Text]
-
Gooding, C., Kemp, P., Smith, C. W. J.
(2003). A Novel Polypyrimidine Tract-binding Protein Paralog Expressed in Smooth Muscle Cells. J. Biol. Chem.
278: 15201-15207
[Abstract]
[Full Text]
-
GROMAK, N., MATLIN, A. J., COOPER, T. A., SMITH, C. W.J.
(2003). Antagonistic regulation of {alpha}-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein. RNA
9: 443-456
[Abstract]
[Full Text]
-
Rooke, N., Markovtsov, V., Cagavi, E., Black, D. L.
(2003). Roles for SR Proteins and hnRNP A1 in the Regulation of c-src Exon N1. Mol. Cell. Biol.
23: 1874-1884
[Abstract]
[Full Text]
-
Kroll, T. T., Zhao, W.-m., Jiang, C., Huber, P. W.
(2003). A homolog of FBP2/KSRP binds to localized mRNAs in Xenopus oocytes. Development
129: 5609-5619
[Abstract]
[Full Text]
-
Zarudnaya, M. I., Kolomiets, I. M., Potyahaylo, A. L., Hovorun, D. M.
(2003). Downstream elements of mammalian pre-mRNA polyadenylation signals: primary, secondary and higher-order structures. Nucleic Acids Res
31: 1375-1386
[Abstract]
[Full Text]
-
Hamilton, B. J., Genin, A., Cron, R. Q., Rigby, W. F. C.
(2003). Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression. Mol. Cell. Biol.
23: 510-525
[Abstract]
[Full Text]
-
Seong, J. Y., Han, J., Park, S., Wuttke, W., Jarry, H., Kim, K.
(2002). Exonic Splicing Enhancer-Dependent Splicing of the Gonadotropin-Releasing Hormone Premessenger Ribonucleic Acid Is Mediated by Tra2{alpha}, a 40-Kilodalton Serine/Arginine-Rich Protein. Mol. Endocrinol.
16: 2426-2438
[Abstract]
[Full Text]
-
Stamm, S.
(2002). Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet
11: 2409-2416
[Abstract]
[Full Text]
-
Xu, Q., Modrek, B., Lee, C.
(2002). Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res
30: 3754-3766
[Abstract]
[Full Text]
-
Gromak, N., Smith, C. W. J.
(2002). A splicing silencer that regulates smooth muscle specific alternative splicing is active in multiple cell types. Nucleic Acids Res
30: 3548-3557
[Abstract]
[Full Text]
-
Soderberg, M., Raffalli-Mathieu, F., Lang, M. A.
(2002). Inflammation Modulates the Interaction of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) I/Polypyrimidine Tract Binding Protein and hnRNP L with the 3'Untranslated Region of the Murine Inducible Nitric-Oxide Synthase mRNA. Mol. Pharmacol.
62: 423-431
[Abstract]
[Full Text]
-
Expert-Bezancon, A., Le Caer, J. P., Marie, J.
(2002). Heterogeneous Nuclear Ribonucleoprotein (hnRNP) K Is a Component of an Intronic Splicing Enhancer Complex That Activates the Splicing of the Alternative Exon 6A from Chicken beta -Tropomyosin Pre-mRNA. J. Biol. Chem.
277: 16614-16623
[Abstract]
[Full Text]
-
Fogel, B. L., McNally, L. M., McNally, M. T.
(2002). Efficient polyadenylation of Rous sarcoma virus RNA requires the negative regulator of splicing element. Nucleic Acids Res
30: 810-817
[Abstract]
[Full Text]
-
Yuan, X., Davydova, N., Conte, M. R., Curry, S., Matthews, S.
(2002). Chemical shift mapping of RNA interactions with the polypyrimidine tract binding protein. Nucleic Acids Res
30: 456-462
[Abstract]
[Full Text]
-
Snee, M., Kidd, G. J., Munro, T. P., Smith, R.
(2002). RNA trafficking and stabilization elements associate with multiple brain proteins. J. Cell Sci.
115: 4661-4669
[Abstract]
[Full Text]
-
Deguillien, M., Huang, S.-C., Moriniere, M., Dreumont, N., Benz, E. J. Jr, Baklouti, F.
(2001). Multiple cis elements regulate an alternative splicing event at 4.1R pre-mRNA during erythroid differentiation. Blood
98: 3809-3816
[Abstract]
[Full Text]
-
Le Guiner, C., Plet, A., Galiana, D., Gesnel, M.-C., Del Gatto-Konczak, F., Breathnach, R.
(2001). Polypyrimidine Tract-binding Protein Represses Splicing of a Fibroblast Growth Factor Receptor-2 Gene Alternative Exon through Exon Sequences. J. Biol. Chem.
276: 43677-43687
[Abstract]
[Full Text]
-
Caputi, M., Zahler, A. M.
(2001). Determination of the RNA Binding Specificity of the Heterogeneous Nuclear Ribonucleoprotein (hnRNP) H/H'/F/2H9 Family. J. Biol. Chem.
276: 43850-43859
[Abstract]
[Full Text]
-
Brudno, M., Gelfand, M. S., Spengler, S., Zorn, M., Dubchak, I., Conboy, J. G.
(2001). Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing. Nucleic Acids Res
29: 2338-2348
[Abstract]
[Full Text]
-
Wagner, E. J., Garcia-Blanco, M. A.
(2001). Polypyrimidine Tract Binding Protein Antagonizes Exon Definition. Mol. Cell. Biol.
21: 3281-3288
[Full Text]
-
Lou, H., Gagel, R. F.
(2001). Alternative Ribonucleic Acid Processing in Endocrine Systems. Endocr. Rev.
22: 205-225
[Abstract]
[Full Text]
-
Côté, J., Dupuis, S., Jiang, Z.-H., Wu, J. Y.
(2001). Caspase-2 pre-mRNA alternative splicing: Identification of an intronic element containing a decoy 3' acceptor site. Proc. Natl. Acad. Sci. USA
10.1073/pnas.031564098v1
[Abstract]
[Full Text]
-
Cote, J., Dupuis, S., Wu, J. Y.
(2001). Polypyrimidine Track-binding Protein Binding Downstream of Caspase-2 Alternative Exon 9 Represses Its Inclusion. J. Biol. Chem.
276: 8535-8543
[Abstract]
[Full Text]
-
Genetta, T., Morisaki, H., Morisaki, T., Holmes, E. W.
(2001). A Novel Bipartite Intronic Splicing Enhancer Promotes the Inclusion of a Mini-exon in the AMP Deaminase 1 Gene. J. Biol. Chem.
276: 25589-25597
[Abstract]
[Full Text]
-
Cote, J., Dupuis, S., Jiang, Z.-H., Wu, J. Y.
(2001). Caspase-2 pre-mRNA alternative splicing: Identification of an intronic element containing a decoy 3' acceptor site. Proc. Natl. Acad. Sci. USA
98: 938-943
[Abstract]
[Full Text]